Indian Shot (Canna Indica L). Leaves Provide Valuable Insights into the Management of Inflammation and Other Associated Disorders Offering Health Benefits Authors: Mohammad Abdullah Taher, Hasin Hasnat, Safaet Alam, Suriya Akter Shompa, Mirola Afroze, Mala Khan, Chuxiao Shao, Shuanghu Wang, Peiwu Geng, Abdullah Al Mamun Published: 2024 ABSTRACT BackgroundThroughout history, plants have played a crucial role in advancing medicinal treatments by providing a diverse range of compounds for the development of innovative therapies. Canna indica L. a tropical herb of the Cannaceae family, also known as Indian shot, has a rich history of traditional use in treating ailments like inflammation, malaria, dysentery, fever, dropsy, and diarrhea.ObjectiveThis comprehensive research invesigates the extract preparation of C. indica leaves using multidisciplinary analytical approaches for this extract in order to shed light on its therapeutic potentials.MethodsThe research, an international collaboration involving researchers from Bangladesh and China, utilized GC-MS/MS analysis to identify bioactive compounds across different C. indica extracts. Biological assays were conducted to assess antimicrobial activity using the disc diffusion method (in vitro), cytotoxicity through the brine shrimp lethality assay (in vitro), analgesic effects via the acetic acid-induced writhing test (in vivo), and antidiarrheal activity with the castor oil-induced diarrhea model (in vivo). Molecular docking studies were performed to determine binding affinities with Epidermal Growth Factor Receptor (EGFR), Dihydrofolate Reductase (DHFR), Delta Opioid Receptor (DOR), Tumor Necrosis Factor-alpha (TNF-α), and Cyclooxygenase-2 (COX-2) receptors.ResultsThe GC-MS/MS analysis identified 35, 43, 27, and 20 compounds in dichloromethane, aqueous, petroleum ether, and ethyl acetate extracts, respectively. The aqueous (AQSF) and dichloromethane (DCMSF) extracts showed notable antimicrobial activity, particularly against gram-negative bacteria. Cytotoxicity tests indicated that ethyl acetate (EASF) and dichloromethane (DCMSF) fractions were potent. Analgesic activity was highest in DCMSF, and antidiarrheal effects were dose-dependent, with DCMSF showing the greatest efficacy. Molecular docking revealed strong affinities of Ergostane-3,5,6,12,25-pentol, 25-acetate, (3.beta.,5.alpha.,6.beta.,12.beta).- for EGFR and Norgestrel for COX-2.ConclusionThis research provides valuable insights into the bioactivity evaluation of C. indica, bridging the gap between its chemical composition and diverse biological effects. The findings contribute to the growing body of knowledge in natural product-based drug discovery and underscore the significance of C. indica as a potential source of novel therapeutic agents to treat inflammation and other disease states. Introduction The search for new therapeutic agents has increasingly led researchers to explore bioactive compounds derived from natural sources, which present a complex and vast network of chemical diversity across various organisms, offering an extensive reservoir of potentially valuable compounds with therapeutic properties.1,2 Bioactive substances, which are defined by their capacity to influence living things biologically, have attracted a lot of attention due to their possible use in the creation of novel medications and medical treatments3,4 The historical significance of natural products in medicine dates back to ancient civilizations, where traditional remedies were often derived from plants, fungi, and marine organisms.5–7 In recent decades, advancements in molecular biology and analytical techniques have intensified the identification, isolation, and characterization of these bioactive compounds,1,8,9 rejuvenating interest in natural product-based drug discovery and fostering a renewed commitment to investigating their therapeutic potential.10–12 Plants provide several classes of phytochemicals such as alkaloids, polyphenols ie flavonoids, phenolic acids, tannins, lignans, and terpenoids including terpenes, and carotenoids, along with glycosides, saponins, polysaccharides, and lipids.13,14 These substances have shown promise in treating several illnesses, such as cancer,15 diabetes mellitus,13 inflammatory conditions,16 and cardiovascular disease.17 Additionally, microbial sources like fungi, bacteria, and actinomycetes are increasingly studied for their bioactive compounds, which offer diverse chemical structures and unique modes of action.18 Notably, around half of the pharmaceutical agents approved by the FDA incorporate natural products or their derivatives.19 Canna indica L., a tropical herb belonging to the Cannaceae20 family, is sometimes called Indian shot, African arrowroot or purple arrowroot,20 features dark green leaves with purple-brown veins and edges, arranged spirally and alternately. The hermaphrodite flowers are crimson, while the green, oblong fruits are slightly echinate. Seeds start white and ripen to black with brown markings. Rhizomes have a yellowish-white interior and a brownish exterior, with a thick coating at maturity. They can be tuberous or stoloniferous, and the roots are thick, cylindrical, and creamy white.21 Though C. indica is native to Mexico, the West Indies, Central America, and South America, it is also found in the Southeast United States and naturalized in Europe, sub-Saharan Africa, Southeast Asia, and Oceania.20 Malaria, dysentery, fever, dropsy, diarrhea, and scrapes and bruises have been treated using C. indica.22 The root was used to cure diaphoretic, diuretic, and dropsy23 and seed juice for the ears. There was a belief that the flowers could heal eye conditions.24,25 Numerous phytochemicals, including Alkaloids, Carbohydrates, Proteins, Flavonoids, Terpenoids, Cardiac glycosides, Steroids, Tannins, Saponins, and Phlobatannins, were found in the C. indica flower, according to a phytochemical study.26 The aerial component of C. indica contains Betulinic acid, Oleanolic acid, and Taraxer-14-en-3-one;27 the flowers include Violaxanthin and β-Carotene; the leaves contain Hemicellulose, Furfural, and Lignin;28 and the rhizomes contain Tricosane, 7-Heneicosyne, 6-Hydroxyicosane, 3,15-Dihydroxy-2-octadecene, 5.8-Heneicosdiyne, and Tetracosane.29 Anthocyanins, found in the flower of C. indica are Cyanidin-3-O-(6”-O-α-rhamnopyranosyl)-β-glucopyranoside, Cyanidin-3-O-(6”-O-α-rhamnopyranosyl)-β-galactopyranoside, Cyanidin-3-O-β-glucopyranoside, and Cyanidin-3-O-β-galactopyranoside.30 Global health concerns such as diarrhea and antimicrobial resistance underscore the urgent need for novel therapeutics. Diarrhea, a significant cause of mortality in developing countries, accounted for 1.1 million deaths in 2019 alone,31,32 with unhygienic conditions and microbial infections (eg, Candida albicans, Escherichia coli, and Salmonella typhi) contributing factors.31,33 Consequently, there is a growing focus on plant-derived antimicrobials as alternatives to conventional antibiotics in addressing these global health challenges.34,35 Additionally, pain, a common consequence of inflammation, arises from the body’s response to injury or infection, with NSAIDs and opioids playing a crucial role in managing pain despite their potential side effects.36,37 The rise in infectious diseases poses a global threat and amplifies the risk of antimicrobial resistance.38 According to the WHO, approximately 10 million deaths are projected to be attributable to AMR by 2050.39 While numerous synthetic drugs are available on the market to treat illnesses, they often come with significant side effects. In contrast, plant-based medicines offer more potent therapeutic benefits and fewer adverse effects.40,41 Therefore, developing new antibacterial drugs from natural sources could be advantageous in curbing bacterial growth and mitigating antimicrobial resistance, as natural plant-based products have recently gained attention as a substantial source of novel, safe, and potent secondary bioactive metabolites with therapeutic potential. This study aimed to characterize the phytochemical composition of C. indica leaf tissue using GC-MS/MS techniques. Employing in vivo and in vitro methodologies, the research explored various biological functions associated with the leaf extract. Additionally, to address the challenge of correlating phytochemical identity with biological activity, an in silico approach was employed to predict the interactions of identified compounds with biological targets, providing preliminary insights into their potential therapeutic mechanisms. This combined in vitro, in vivo, and in silico assessment provides a comprehensive investigation aiming to bridge the gap between chemical composition and biological efficacy, thereby unveiling C. indica’s potential therapeutic properties. Materials and Methods Drugs and Chemicals Analytical-grade medicines and substances were used in this investigation. Methanol, Petroleum ether, Dichloromethane, Ethyl-acetate, and Tween-80 were purchased from Merck (Darmstadt, Germany). Azithromycin, Amoxicillin, Ciprofloxacin, Diazepam, and Loperamide were collected from the local market, which are manufactured by Square Pharmaceuticals Ltd. or Renata Ltd. in Bangladesh. Test Organisms The antimicrobial assay utilized gram-positive bacteria (Sarcina lutea, Bacillus megaterium, Staphylococcus aureus, Bacillus cereus, and Bacillus subtilis) and gram-negative bacteria (Vibrio mimicus, Pseudomonas aeruginosa, Salmonella typhi, Salmonella paratyphi, Escherichia coli, Shigella dysenteriae, and Vibrio parahemolyticus) sourced from the University of Dhaka, Bangladesh. Plant Collection In November 2022, leaves from mature plants of Canna indica L. were collected from the hill regions of Bandarban (22.1961° N, 92.2176° E), Chittagong, Bangladesh. Khandaker Kamrul Islam, Senior Scientific Officer, Bangladesh National Herbarium, located in Mirpur, Dhaka, verified the authenticity of the plant samples. The voucher specimen of the plant has been preserved in the herbarium for future reference, cataloged under the accession number DACB 66976. Plant Extraction The leaves of C. indica L. were acquired from the wild, subjected to shade drying, and pulverized using a mechanical grinder. A total of 800 g of leaf powder was accurately measured and placed into a 5 L round bottom clean flask. The powder was wholly submerged in 2.5 L of distilled methanol, which covered approximately two-thirds of the flask’s volume. The mixture was left to incubate in normal laboratory conditions for 15 days, during which it was periodically shaken and stirred. Following incubation, the mixture underwent filtration, and the filtered extract was concentrated using a rotary evaporator.42 A total of 45.56 g of slurry crude extract (around 5.695%) yielded. The modified Kupchan Partitioning method43 was employed for solvent-solvent partitioning. Around 30 g of crude methanol extract (CME) obtained from C. indica leaves was mixed with 200 mL of distilled methanol and then subjected to fractionation. This process used 400 mL (200 mL for 2 times) each of petroleum ether (PET), dichloromethane (DCM), ethyl acetate (EA), and distilled water, in that order, based on an increasing relative polarity index. After the partitioning process, rotary evaporation was utilized to yield the petroleum ether-soluble fraction (PESF, 2.35 g; 2.94 mg/g of dry weight of plant material), the dichloromethane-soluble fraction (DCMSF, 3.43 g; 4.29 mg/g of dry weight of plant material), the ethyl acetate-soluble fraction (EASF, 1.68 g; 2.10 mg/g of dry weight of plant material), and the aqueous-soluble fraction (AQSF, 1.6 g; 2.00 mg/g of dry weight of plant material). Phytochemical Assay Gc-Ms/Ms Using an electronic ionization detector along with GC–MS/MS (Shimadzu, Japan; Model GC–MS TQ 8040) analysis, the bioactive chemicals from the leaves of C. indica plants were examined. A 50 °C fused silica capillary column (Rxi5Sil MS, 30 m, 0.25 mm ID, and 0.25 μm) was utilized. After that, the samples were collected at 250 °C in a fix split mode. Preheating the oven took one minute at 500 °C, two minutes at 200 °C, and seven minutes at 300 °C. The electron multiplier was tuned to 900 V, and the ionization voltage was increased to 70 eV. The GC-MS unknown spectra were then contrasted with those of recognized compounds kept in the NIST or Wiley libraries.44,45 After that, the compound names, molecular formulae, and weights were established. It took a total of 39 minutes to complete the GC-MS run. Compound Quantification and Identification Quantification of each component involved comparing its average peak area to the total area, allowing the determination of proportional percentages. Identification of compounds via GC–MS spectra utilized the National Institute of Standards and Technology (NIST) database, which houses approximately 62,000 patterns.46 Unknown component spectra were compared against both the NIST database’s extensive collection and known components stored therein to ensure accurate identification during the GC–MS/MS experiment. In vitro Assay Antimicrobial Test The antimicrobial efficacy of four fractions derived from the methanol extract of C. indica was evaluated using the disc diffusion technique.47 Sterilized filter paper discs (6 mm diameter), each containing 100 µg of DCMSF, PESF, EASF, or AQSF, were placed on nutrient agar previously inoculated with test bacteria and fungi strains. Commercial antibiotic discs (Azithromycin, Amoxicillin, and Ciprofloxacin, 30 µg/disc) served as positive controls, while blank discs served as negative controls. The plates were inverted and stored at 4°C for 24 hours to ensure even distribution, followed by incubation at 37°C for another 24 hours. Zones of inhibition, indicative of antibacterial activity, were measured in millimetres. The test was repeated 3 times for each sample, and the result was expressed as mean ± Standard Deviation (SD). In vitro Cytotoxic Test The study utilized brine shrimp (Artemia salina leach) eggs exposed to varying concentrations of a solution prepared by dissolving test samples in dimethyl sulfoxide.48 The experimental setup involved introducing live shrimp into test tubes containing simulated seawater. After 24 hours, the mortality rates were assessed, employing a serial dilution method to generate a range of concentrations from the stock solution. Each of the fractionated extractives (test samples) and vincristine standard solution (positive control) were serially diluted, starting from a concentration of 400 μg/mL to 0.78125 μg/mL and from a concentration of 20 μg/mL to 0.039 μg/mL, respectively. The LC50, representing the concentration causing 50% shrimp mortality within the given timeframe, was determined as a measure of toxicity. The mortality percentage for each dilution was computed using the formula % mortality = (Number of dead shrimp / Number of shrimps introduced) × 100. This approach allowed for the assessment of the extract’s impact on brine shrimp survival across various concentrations. Molecular Docking Study Software A computational methodology was utilized to evaluate the binding affinities of compounds extracted from the leaves extract of C. indica towards different target proteins. The analysis involved the application of various software tools, including PyRx, PyMOL 2.3, Discovery Studio 4.5, and Swiss PDB Viewer, to perform comprehensive assessments of the molecular interactions.49 Ligand Preparation The three-dimensional Structure Data File (SDF) representations of the compounds listed in the table were sought and retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov/; accessed on 17 November 2023). Additionally, the 3D SDF structures for five reference compounds—Lapatinib (PubChem CID_208908), Ciprofloxacin (PubChem CID_2764), Loperamide (PubChem CID_3955), and Diclofenac (PubChem CID_3033) were acquired from various sources.50–54 The ligand library was constructed by systematically importing both the listed compounds and the standard references into Discovery Studio 4.5. Subsequently, all compounds were optimized using the Pm6 semiempirical method, enhancing the precision of the docking process.49 Receptor Selection A total of 103 compounds derived from the methanol, DCM, pet ether, and ethanol fractions of C. indica leaf extract underwent computerized docking analysis to investigate their potential cytotoxic, antimicrobial, hypoglycemic, anti-inflammatory, and analgesic properties. The assessment of cytotoxicity involved the utilization of the 3D crystal structure of the epidermal growth factor receptor (EGFR) [PDB ID: 1XKK],52 retrieved from the Protein Data Bank (https://www.rcsb.org/; accessed on 19 October 2023). Similarly, the 3D structures of dihydrofolate reductase (DHFR) [PDB ID: 4M6J], human delta-opioid receptor (DOR) [PDB ID: 4RWD], Tumor necrosis factor-α (TNF-α) [PDB ID: 6VI4], and cyclooxygenase-2 (COX-2) [PDB ID: 1CX2] were obtained from the same source for the evaluation of their antimicrobial, hypoglycemic, anti-diarrheal, and analgesic activities, respectively.50,51,53,54 Ligand- Receptor Binding The assessment of affinities and potential binding patterns between phytocompounds and target molecules involved a sophisticated computer-aided approach by creating ligand-protein interaction diagrams. The utilization of the PyRxAutodock Vina software, known for its advanced capabilities in molecular drug-protein linking, employed a semi-flexible modeling approach during the docking process. A literature-based selection of specific amino acids with their respective IDs was meticulously curated for individual receptors to ensure precision in target docking. The preparation of the protein involved loading and formatting it as the necessary macromolecule, carefully ensuring that ligands are exclusively bound to the intended target. For optimal docking against these selected macromolecules, the ligands’ SD files were imported and converted into pdbqt format using the Open Babel tool within the PyRxAutoDock Vina software. The definition of active amino sites within grid boxes was accomplished through grid mapping, with the specified center and dimension axes maintained according to the details provided in the accompanying Table 1. Default supportive functions were retained during this stage. Table 1Selection of Target Site and Grid Mapping of Target ReceptorsReceptorStandardTarget Binding SitesReferenceGrid boxEGFRLapatinibLeu 718, Val 726, Ala 743, Lys 745, Met 766, Lys 775, Arg 776, Leu 777, Leu 788, Thr 790, Gln 791, Leu 792, Met 793, Gly 796, Cys 797, Leu 799, Asp 800, Arg 803, Leu 844, Thr 854, Asp 855, Phe 856[52]Centerx = 15.9006706175, y = 34.5810564289, z = 35.8511159995Dimensionx = 24.7784116406, y = 19.7826045166, z = 32.3280197617DHFRCiprofloxacinAla 9, Ile 16, Leu 93, Ser 92, Arg9 1, Arg 77, Glu 78, Ser 76, Leu 75, Lys 54, Val 120, Ser 119, Lys 55, Thr 56, Ser 118, Gly 117[54]Centerx = 3.22631914693, y = −3.74047127586, z = −18.5356969616Dimensionx = 20.8747603874, y = 27.8891050273, z = 27.2979925831DORLoperamideA chain- Val 62, Leu 65, Gly 66, Leu 69, Val 70, Phe 72, Gly 73, Tyr 77, Pro 315, Val 316, Ala 319, Phe 325, Cys 328, Phe 329, Gln 331, Leu 332[51]Centerx = −54.7882736979, y = −0.0619991477186, z = 54.9119221162Dimensionx = 31.2223397671, y = 24.3896375603, z = 27.4247000789TNF-αDiclofenacA chain- Tyr 59, Tyr 119, Leu 120, Gly 121, Tyr 151; B chain- Tyr 59, Ser 60, Gln 61, Tyr 119, Leu 120, Gly 121[53]Centerx = −19.8668590785, y = 74.1791111098, z = 37.6236254721Dimensionx = 19.55913465, y = 22.2400774665, z = 15.1069916676COX-2DiclofenacHis 90, Gln 192, Val 349, Leu 352, Ser 353, Tyr 355, Tyr 385, Ala 516, Phe 518, Val 523, Ala 527, and Ser 530[50]Centerx = 23.1078401223, y = 21.112183808, z = 15.5157206145Dimensionx = 21.543116081, y = 18.449889569, z = 24.2116427641 Table 1Selection of Target Site and Grid Mapping of Target ReceptorsReceptorStandardTarget Binding SitesReferenceGrid boxEGFRLapatinibLeu 718, Val 726, Ala 743, Lys 745, Met 766, Lys 775, Arg 776, Leu 777, Leu 788, Thr 790, Gln 791, Leu 792, Met 793, Gly 796, Cys 797, Leu 799, Asp 800, Arg 803, Leu 844, Thr 854, Asp 855, Phe 856[52]Centerx = 15.9006706175, y = 34.5810564289, z = 35.8511159995Dimensionx = 24.7784116406, y = 19.7826045166, z = 32.3280197617DHFRCiprofloxacinAla 9, Ile 16, Leu 93, Ser 92, Arg9 1, Arg 77, Glu 78, Ser 76, Leu 75, Lys 54, Val 120, Ser 119, Lys 55, Thr 56, Ser 118, Gly 117[54]Centerx = 3.22631914693, y = −3.74047127586, z = −18.5356969616Dimensionx = 20.8747603874, y = 27.8891050273, z = 27.2979925831DORLoperamideA chain- Val 62, Leu 65, Gly 66, Leu 69, Val 70, Phe 72, Gly 73, Tyr 77, Pro 315, Val 316, Ala 319, Phe 325, Cys 328, Phe 329, Gln 331, Leu 332[51]Centerx = −54.7882736979, y = −0.0619991477186, z = 54.9119221162Dimensionx = 31.2223397671, y = 24.3896375603, z = 27.4247000789TNF-αDiclofenacA chain- Tyr 59, Tyr 119, Leu 120, Gly 121, Tyr 151; B chain- Tyr 59, Ser 60, Gln 61, Tyr 119, Leu 120, Gly 121[53]Centerx = −19.8668590785, y = 74.1791111098, z = 37.6236254721Dimensionx = 19.55913465, y = 22.2400774665, z = 15.1069916676COX-2DiclofenacHis 90, Gln 192, Val 349, Leu 352, Ser 353, Tyr 355, Tyr 385, Ala 516, Phe 518, Val 523, Ala 527, and Ser 530[50]Centerx = 23.1078401223, y = 21.112183808, z = 15.5157206145Dimensionx = 21.543116081, y = 18.449889569, z = 24.2116427641 Selection of Target Site and Grid Mapping of Target Receptors Subsequently, a comprehensive docking analysis was executed using AutoDock Vina (version 1.1.2) to determine the ligands’ affinity for their respective macromolecules. The final step involved result interpretation, where BIOVIA Discovery Studio version 4.5 was employed to predict the most suitable 2D and 3D models, adding depth and insight to the overall analysis. ADME/T Analysis In the domain of computer-based drug design, there is an increasingly prevalent focus on executing comprehensive pharmacokinetic studies that delve into critical facets such as absorption, distribution, metabolism, excretion, and toxicology. Moreover, the evaluation of drug-likeness through bioavailability studies has emerged as a pivotal component in drug discovery endeavors. Integral to these analyses are ADMET studies, which play a crucial role in unravelling the pharmacological characteristics of compounds. Accessible through resources like http://biosig.unimelb.edu.au/pkcsm/prediction, these ADMET analyses provide essential insights7. Online platforms such as Swiss ADME (http://www.sib.swiss) have become widely adopted for predicting drug-likeness by leveraging Lipinski rules and pharmacokinetic parameters. According to Lipinski’s criteria, a compound is deemed orally accessible if it satisfies specific conditions, including a molecular weight below 500 amu, fewer than 5 hydrogen bond donor sites, fewer than 10 hydrogen bond acceptor sites, and a lipophilicity value (LogP) of ≤5.49 This set of criteria serves as a guideline for assessing the potential oral bioavailability of compounds. In vivo Assay Animal Preparation The experimental animals for this study were Swiss-albino mice of both sexes, weighing between 25 and 30 grams, sourced from the Animal Resources Facility at the International Centre for Diarrheal Diseases (ICDDR, B). Prior to the commencement of the study, a one-week acclimatization period was provided in the new environment. Throughout the experimental phase, the mice were housed in a well-ventilated animal facility with a temperature of 25 °C, relative humidity maintained between 55% and 65%, and a 12-hour light/dark cycle. The mice had ad libitum access to standard laboratory food and drinking water. An intraperitoneal overdose of ketamine HCl (100 mg/kg) and xylazine (7.5 mg/kg) was administered to euthanize the mice at the end of the experiment, following the previously established protocol delineated by Zimmermann, 1983.55 The “Animal Ethics Number” for the test animal models of this research is 2023–01-04/SUB/A-ERC/002 and ratified by the Animal Ethics Committee, State University of Bangladesh. All experiments undertaken were executed in strict adherence to the approved Animal Use Protocol, as sanctioned by the Ethics Committee, and in full compliance with the Guidelines established by the United States National Institutes of Health for the Care and Use of Laboratory Animals. Moreover, the directives and recommendations set forth by the Federation of European Laboratory Animal Science Associations (FELASA) were meticulously followed to minimize any discomfort or distress experienced by the laboratory subjects.56 In vivo Oral Toxicity Test The mice were administered a high oral dose of 2000 mg/kg body weight of methanol-soluble crude extract obtained from C. indica under standard laboratory conditions using the OECD Guidelines 420 fixed-dose method.57 After the treatment, different parameters were examined for 72 hours. The results showed no signs of allergic reactions, changes in behavior (such as drowsiness or excitability), or any instances of mortality. As a result, doses of 200 and 400 mg/kg (body weight, taken orally) were selected for the investigation. In vivo Analgesic Test To evaluate the peripheral analgesic effect of C. indica in albino mice, we conducted the acetic acid-induced writhing test58. Diclofenac sodium (50 mg/kg body weight) was administered intraperitoneally as a standard reference. In contrast, the treatment groups received different doses of C. indica extract, specifically 200 and 400 mg/kg body weight, with each type of extract being administered orally at both dosage levels to form two groups. For DCMSF, groups III and IV were created, with group III receiving 200 mg/kg and group IV receiving 400 mg/kg. For AQSF, groups V and VI were assigned, with group V administered 200 mg/kg and group VI 400 mg/kg. Similarly, groups VII and VIII were treated with PESF, where group VII received the 200 mg/kg dose and group VIII received the 400 mg/kg dose. Finally, for EASF, groups IX and X were created, with group IX receiving 200 mg/kg and group X 400 mg/kg, while the negative control group received only distilled water. Thirty minutes after the administration of these samples, glacial acetic acid (0.1 mL/30 mg body weight) was injected intraperitoneally. For each group, the number of abdominal constrictions, or writhes, was counted from 5 minutes to 10 minutes post-acetic acid injection. The percentage inhibition of writhing, indicating peripheral analgesic activity, was then calculated using the formula: % inhibition of writhing= (Wcontrol−Wtest)/Wcontrol×100%. where Wtest represents the average number of writhes in the test group, and Wcontrol represents the average number in the control group. Castrol Oil-Induced Diarrhea Diarrhea was induced by administering 0.5 mL of castor oil to mice, and only those exhibiting diarrhea were included in the experiment.56 The mice, divided into ten groups with four members each, were given different treatments. Group I received a control vehicle (distilled water with 1% Tween-80), and Group II was treated with loperamide (2 mg/kg, b.w; i.p), a standard anti-motility agent. The treatment groups were administered different quantities of C. indica extract, specifically 200 and 400 mg/kg body weight. Groups III and IV were provided DCMSF, V and VI received AQSF, and VII and VIII were given PESF, while groups IX and X were treated with EASF. Following the administration of test samples, each mouse received 0.5 mL of castor oil after one hour, and they were individually placed in a box with clear paper on the floor. The observational period recorded the onset of duration, weight of wet stools, total number, and the total weight of faecal yields. The percentage of diarrheal inhibition (% of defecation inhibition) was calculated using the previously mentioned equation. The animals in all groups had free access to water overnight during the study. Statistical Analysis GraphPad Prism 5.2 (GraphPad Software, Inc., La Jolla, CA, United States) was employed for statistical analysis, and the results were expressed as mean ± standard error (SEM). Statistical significance was determined using one-way analysis of variance (ANOVA) followed by Dunnett’s test. Significance levels were indicated by *p < 0.5, **p < 0.01, and ***p < 0.001. Results Phytochemicals Identified from GC–MS/MS Analysis of DCM Extract of Canna Indica GC-MS/MS screening of the DCM extract of C. indica revealed the presence of 35 compounds. The peak area % of each compound was determined to represent the relative concentration of the compound. Among the identified compounds, 1-Heptatriacontanol (13.3%), 9-Octadecenamide, (Z)- (6.44%), Eicosyl isopropyl ether (5.07%), 11-Methyltricosane (3.82%) were found to have the most prevalence (Figure 1, Table 2). Table 2Phytochemicals Identified from GC–MS/MS Analysis of Dichloromethane (DCM) Extract of Canna IndicaS/NCompound NameRet. TimeConc. %m/zMS similarityFiguresAldehyde12-[4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl]cyclohex-1-en-1-carboxaldehyde17.511.231217822-Butenal, 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-17.072.358179Alcohol31,1,4,7-Tetramethyldecahydro-1H-cyclopropa[e]azulene-4,7-diol13.741.991117643,7,11,15-Tetramethyl-2-hexadecen-1-ol14.311.7168875Thunbergol16.300.551377761-Heptatriacotanol23.1313.3817171-Heptatriacotanol23.744.455776Ketone8Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1S)-7.272.6895979(S,E)-4-Hydroxy-3,5,5-trimethyl-4-(3-oxobut-1-en-1-yl)cyclohex-2-enone13.870.991247910Curcumenone14.490.676891112(1H)-Azulenone, 4,5,6,7,8,8a-hexahydro-8a-methyl-, (S)-14.972.7––121-(4-Hydroxy-3-isopropenyl-4,7,7-trimethyl-cyclohept-1-enyl)-ethanone20.550.7812468134,7-Methanofuro[3,2-c]oxacycloundecin-6(4H)-one, 7,8,9,12-tetrahydro-3,11-dimethyl-20.911.699168146-(1-Hydroxymethylvinyl)-4,8a-dimethyl-3,5,6,7,8,8a-hexahydro-1H-naphthalen-2-one16.491.3810580Terpene15Isoborneol7.442.53959516endo-Borneol7.530.94959617Aromadendrene oxide-(2)15.070.58798418(4R,4aR)-4,4a-Dimethyl-6-(prop-1-en-2-yl)-1,2,3,4,4a,7-hexahydronaphthalene14.030.951597719Ergostane-3,5,6,12,25-pentol, 25-acetate, (3.beta.,5.alpha.,6.beta.,12.beta).-14.390.86717720Dihydroartemisinin, 6-deshydro-5-deshydroxy-3-desoxy-20.821.4312472Hydrocarbon21Biphenylene, 1,2,3,6,7,8,8a,8b-octahydro-4,5-dimethyl-21.691.611457022Eicosane23.250.5579123Triacontane, 1-bromo-25.261.1757762411-Methyltricosane25.423.8215364Others251S,3R,4S,5R,6S-1-Hydroxy-2,2,3,4,5,6-hexamethyl-8-oxo-7,9-dioxatricyclo[4.2.1.0(3,5)]nonane24.886.161247126Cyclohexene, 4-pentyl-1-(4-propylcyclohexyl)-13.30.576772273-Butoxy-1,1,1,7,7,7-hexamethyl-3,5,5-tris(trimethylsiloxy)tetrasiloxane15.410.54737328Octasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-hexadecamethyl-17.600.54736529Acetic acid, tricyclo[3.3.1.1(3,7)]decylidene-, ethyl ester18.320.651746930(Chroman-7-yl)methylamine18.740.641636931Cyclononasiloxane, octadecamethyl-19.830.4973703211.beta.-Hydroxyprogesterone21.250.6512467339-Octadecenamide, (Z)-22.566.445994342,3:5,6-Di-O-1-Cyclohexylieden-1,4-cyclohexandiallylether25.331.35576035Eicosyl isopropyl ether26.245.075770 Figure 1GC–MS/MS Chromatogram of Dichloromethane extract of Canna indica. Table 2Phytochemicals Identified from GC–MS/MS Analysis of Dichloromethane (DCM) Extract of Canna IndicaS/NCompound NameRet. TimeConc. %m/zMS similarityFiguresAldehyde12-[4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl]cyclohex-1-en-1-carboxaldehyde17.511.231217822-Butenal, 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-17.072.358179Alcohol31,1,4,7-Tetramethyldecahydro-1H-cyclopropa[e]azulene-4,7-diol13.741.991117643,7,11,15-Tetramethyl-2-hexadecen-1-ol14.311.7168875Thunbergol16.300.551377761-Heptatriacotanol23.1313.3817171-Heptatriacotanol23.744.455776Ketone8Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1S)-7.272.6895979(S,E)-4-Hydroxy-3,5,5-trimethyl-4-(3-oxobut-1-en-1-yl)cyclohex-2-enone13.870.991247910Curcumenone14.490.676891112(1H)-Azulenone, 4,5,6,7,8,8a-hexahydro-8a-methyl-, (S)-14.972.7––121-(4-Hydroxy-3-isopropenyl-4,7,7-trimethyl-cyclohept-1-enyl)-ethanone20.550.7812468134,7-Methanofuro[3,2-c]oxacycloundecin-6(4H)-one, 7,8,9,12-tetrahydro-3,11-dimethyl-20.911.699168146-(1-Hydroxymethylvinyl)-4,8a-dimethyl-3,5,6,7,8,8a-hexahydro-1H-naphthalen-2-one16.491.3810580Terpene15Isoborneol7.442.53959516endo-Borneol7.530.94959617Aromadendrene oxide-(2)15.070.58798418(4R,4aR)-4,4a-Dimethyl-6-(prop-1-en-2-yl)-1,2,3,4,4a,7-hexahydronaphthalene14.030.951597719Ergostane-3,5,6,12,25-pentol, 25-acetate, (3.beta.,5.alpha.,6.beta.,12.beta).-14.390.86717720Dihydroartemisinin, 6-deshydro-5-deshydroxy-3-desoxy-20.821.4312472Hydrocarbon21Biphenylene, 1,2,3,6,7,8,8a,8b-octahydro-4,5-dimethyl-21.691.611457022Eicosane23.250.5579123Triacontane, 1-bromo-25.261.1757762411-Methyltricosane25.423.8215364Others251S,3R,4S,5R,6S-1-Hydroxy-2,2,3,4,5,6-hexamethyl-8-oxo-7,9-dioxatricyclo[4.2.1.0(3,5)]nonane24.886.161247126Cyclohexene, 4-pentyl-1-(4-propylcyclohexyl)-13.30.576772273-Butoxy-1,1,1,7,7,7-hexamethyl-3,5,5-tris(trimethylsiloxy)tetrasiloxane15.410.54737328Octasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-hexadecamethyl-17.600.54736529Acetic acid, tricyclo[3.3.1.1(3,7)]decylidene-, ethyl ester18.320.651746930(Chroman-7-yl)methylamine18.740.641636931Cyclononasiloxane, octadecamethyl-19.830.4973703211.beta.-Hydroxyprogesterone21.250.6512467339-Octadecenamide, (Z)-22.566.445994342,3:5,6-Di-O-1-Cyclohexylieden-1,4-cyclohexandiallylether25.331.35576035Eicosyl isopropyl ether26.245.075770 Phytochemicals Identified from GC–MS/MS Analysis of Dichloromethane (DCM) Extract of Canna Indica GC–MS/MS Chromatogram of Dichloromethane extract of Canna indica. Phytochemicals Identified from GC–MS/MS Analysis of Aqueous Extract of Canna Indica Our analysis of a methanol-based extract of C. indica unveiled a significant discovery-The presence of 43 distinct compounds. Notably, the most abundant compounds were Curcumenol (12.98%), Phytol (8.66%), (R)-3,5,8a-Trimethyl-7,8,8a,9-tetrahydronaphtho[2,3-b]furan-4(6H)-one (8.3%), 1-Heptatriacontanol (3.06%), Neophytadiene(2.94%), Zederone (2.82%) (Figure 2, Table 3). Table 3Phytochemicals Identified from GC–MS/MS Analysis of Aqueous (AQ) Extract of Canna IndicaS/NCompound NameRet. TimeConc. %m/zMS similarityFiguresAldehyde1(1aR,4aS,8aS)-4a,8,8-Trimethyl-1,1a,4,4a,5,6,7,8-octahydrocyclopropa[d]naphthalene-2-carbaldehyde16.52.029178Alcohol2Isospathulenol12.061.331199131,1,4,7-Tetramethyldecahydro-1H-cyclopropa[e]azulene-4,7-diol13.751.59119–43,7,11,15-Tetramethyl-2-hexadecen-1-ol14.910.65819051H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, [1ar-(1a.alpha.,4a.alpha.,7.beta.,7a.beta.,7b.alpha).]-15.870.89119766(1aR,3aS,7S,7aS,7bR)-1,1,3a,7-Tetramethyldecahydro-1H-cyclopropa[a]naphthalen-7-ol17.071.3481767Cycloprop[e]indene-1a,2(1H)-dimethanol, 3a,4,5,6,6a,6b-hexahydro-5,5,6b-trimethyl-, (1a.alpha.,3a.beta.,6a.beta.,6b.alpha).-(-)21.721.26916683-Buten-2-ol, 2-methyl-4-(1,3,3-trimethyl-7-oxabicyclo[4.1.0]hept-2-yl)-22.80.81555991-Heptatriacotanol23.113.06817410Phytol18.438.667197Ketone113,3-Dimethoxy-2-butanone3.740.79897912(R)-3,5,8a-Trimethyl-7,8,8a,9-tetrahydronaphtho[2,3-b]furan-4(6H)-one11.758.312284132-Pentadecanone, 6,10,14-trimethyl-14.391.42717914Curcumenone14.501.936890151-Oxaspiro[2.5]octan-4-one, 2,2,6-trimethyl-, cis-20.951.115547161-Pentanone,1-(1-[hydroxy(phenyl)methyl]cyclobutyl])20.981.095552Terpene17Caryophyllene oxide11.671.16797518Epicurzerenone11.871.0712283191,3,6,10-Cyclotetradecatetraene, 3,7,11-trimethyl-14-(1-methylethyl)-, [S-(E,Z,E,E)]-12.981.111057920Curcumenol A13.1912.981059021(4R,4aR)-4,4a-Dimethyl-6-(prop-1-en-2-yl)-1,2,3,4,4a,7-hexahydronaphthalene14.040.8291–22Neophytadiene14.312.94689223Caryophyllene oxide16.340.68133–24Zederone16.952.821198825Corymbolone21.151.0812463Esters26Butyl 6,9,12,15-octadecatetraenoate10.770.81917427n-Propyl 5,8,11,14,17-eicosapentaenoate14.121.851077228Cholest-5-en-3-ol (3.beta).-, tetradecanoate37.081.69737429Acetic acid, 2-(2-acetoxy-2,5,5,8a-tetramethyldecalin-1-yl)-24.941.112459Hydrocarbon30Decane, 1-bromo-2-methyl-20.010.85576131Dodecane, 3-cyclohexyl-22.771.426956322-Methyltetracosane23.240.745779332,7-Octadiene, 1-butoxy-24.560.77153Others34Cyclohexasiloxane, dodecamethyl-13.421.0873–35Danazol13.80.97109–361,4-Methanocycloocta[d]pyridazine, 1,4,4a,5,6,9,10,10a-octahydro-11,11-dimethyl-, (1.alpha.,4.alpha.,4a.alpha.,10a.alpha).-14.782.06107–371H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, [1ar-(1a.alpha.,4a.alpha.,7.beta.,7a.beta.,7b.alpha).]-16.191.07917738Pseduosarsasapogenin-5,20-dien methyl ether17.611.1735639alpha.-Chlorocyclooctanone oxime18.241.09536240Norethindrone19.902.2253–41Phytol, acetate20.090.8857–4211.beta.-Hydroxyprogesterone21.231.6712464431-Methyl-4-nitro-5-[(1,2-dimethyl-3-hydroxybutyl)amino]-(1H)-imidazole22.840.75554 Figure 2GC–MS/MS Chromatogram of Aqueous extract of Canna indica. Table 3Phytochemicals Identified from GC–MS/MS Analysis of Aqueous (AQ) Extract of Canna IndicaS/NCompound NameRet. TimeConc. %m/zMS similarityFiguresAldehyde1(1aR,4aS,8aS)-4a,8,8-Trimethyl-1,1a,4,4a,5,6,7,8-octahydrocyclopropa[d]naphthalene-2-carbaldehyde16.52.029178Alcohol2Isospathulenol12.061.331199131,1,4,7-Tetramethyldecahydro-1H-cyclopropa[e]azulene-4,7-diol13.751.59119–43,7,11,15-Tetramethyl-2-hexadecen-1-ol14.910.65819051H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, [1ar-(1a.alpha.,4a.alpha.,7.beta.,7a.beta.,7b.alpha).]-15.870.89119766(1aR,3aS,7S,7aS,7bR)-1,1,3a,7-Tetramethyldecahydro-1H-cyclopropa[a]naphthalen-7-ol17.071.3481767Cycloprop[e]indene-1a,2(1H)-dimethanol, 3a,4,5,6,6a,6b-hexahydro-5,5,6b-trimethyl-, (1a.alpha.,3a.beta.,6a.beta.,6b.alpha).-(-)21.721.26916683-Buten-2-ol, 2-methyl-4-(1,3,3-trimethyl-7-oxabicyclo[4.1.0]hept-2-yl)-22.80.81555991-Heptatriacotanol23.113.06817410Phytol18.438.667197Ketone113,3-Dimethoxy-2-butanone3.740.79897912(R)-3,5,8a-Trimethyl-7,8,8a,9-tetrahydronaphtho[2,3-b]furan-4(6H)-one11.758.312284132-Pentadecanone, 6,10,14-trimethyl-14.391.42717914Curcumenone14.501.936890151-Oxaspiro[2.5]octan-4-one, 2,2,6-trimethyl-, cis-20.951.115547161-Pentanone,1-(1-[hydroxy(phenyl)methyl]cyclobutyl])20.981.095552Terpene17Caryophyllene oxide11.671.16797518Epicurzerenone11.871.0712283191,3,6,10-Cyclotetradecatetraene, 3,7,11-trimethyl-14-(1-methylethyl)-, [S-(E,Z,E,E)]-12.981.111057920Curcumenol A13.1912.981059021(4R,4aR)-4,4a-Dimethyl-6-(prop-1-en-2-yl)-1,2,3,4,4a,7-hexahydronaphthalene14.040.8291–22Neophytadiene14.312.94689223Caryophyllene oxide16.340.68133–24Zederone16.952.821198825Corymbolone21.151.0812463Esters26Butyl 6,9,12,15-octadecatetraenoate10.770.81917427n-Propyl 5,8,11,14,17-eicosapentaenoate14.121.851077228Cholest-5-en-3-ol (3.beta).-, tetradecanoate37.081.69737429Acetic acid, 2-(2-acetoxy-2,5,5,8a-tetramethyldecalin-1-yl)-24.941.112459Hydrocarbon30Decane, 1-bromo-2-methyl-20.010.85576131Dodecane, 3-cyclohexyl-22.771.426956322-Methyltetracosane23.240.745779332,7-Octadiene, 1-butoxy-24.560.77153Others34Cyclohexasiloxane, dodecamethyl-13.421.0873–35Danazol13.80.97109–361,4-Methanocycloocta[d]pyridazine, 1,4,4a,5,6,9,10,10a-octahydro-11,11-dimethyl-, (1.alpha.,4.alpha.,4a.alpha.,10a.alpha).-14.782.06107–371H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, [1ar-(1a.alpha.,4a.alpha.,7.beta.,7a.beta.,7b.alpha).]-16.191.07917738Pseduosarsasapogenin-5,20-dien methyl ether17.611.1735639alpha.-Chlorocyclooctanone oxime18.241.09536240Norethindrone19.902.2253–41Phytol, acetate20.090.8857–4211.beta.-Hydroxyprogesterone21.231.6712464431-Methyl-4-nitro-5-[(1,2-dimethyl-3-hydroxybutyl)amino]-(1H)-imidazole22.840.75554 Phytochemicals Identified from GC–MS/MS Analysis of Aqueous (AQ) Extract of Canna Indica GC–MS/MS Chromatogram of Aqueous extract of Canna indica. Phytochemicals Identified from GC–MS/MS Analysis of Petroleum Ether Extract of Canna Indica Our meticulous screening of the petroleum ether fraction was instrumental in the discovery of a total of 27 compounds. Among these, Benzene, (2-iodoethyl) – (31.28%), Tetradecane (6.13%), Cyclopentene, 1-ethenyl-3-methylene-(6.05%), Hexadecane (5.56%), Epicurzerenone (5.48%), Ethylbenzene (4.69%) were found to have the most comparative concentration (Figure 3, Table 4). Table 4Phytochemicals Identified from GC–MS/MS Analysis of Petroleum Ether (PET) Extract of Canna IndicaS.NCompound NameRet. TimeConc. %m/zMS similarityFiguresKetone1Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1S)-7.2422.639597Alcohol2Z-10-Pentadecen-1-ol11.6711.68558532,4-Pentadien-1-ol, 3-pentyl-, (2Z)-16.9591.4183794Phytol18.4372.357197Terpene5Isoborneol7.4261.195956Caryophyllene10.120.9691957alpha.-Guaiene10.7710.98191798Epicurzerenone11.7495.48122889Curcumenol13.1922.6510576Ester10Dodecanoic acid, phenylmethyl ester29.1490.86577711Benzenepropanoic acid, 3.5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester30.6881.345783Hydrocarbon12Cyclopentane, 1,1,3,4-tetramethyl-, trans-3.5322.79558713Cyclohexane, 1,2,4-trimethyl-3.5751.58698514Cyclohexane, 1,2,4-trimethyl-3.7121.16699215Ethylbenzene3.7684.69919216Benzene, (2-iodoethyl)-3.86831.28928217Cyclopentene, 1-ethenyl-3-methylene-4.1426.05919418Nonane4.193.42579619Dodecane7.71.17579820Tetradecane9.7396.13579421Hexadecane11.5795.56579622Heneicosane13.8183.725797237-Heptadecene, 1-chloro-14.0131.19558324Cyclopropane, 2-(1,1-dimethyl-2-propenyl)-1,1-dimethyl-15.2351.39828425Heneicosane16.6752.33579726Heneicosane19.8791.445795Other279-Octadecenamide, (Z)-22.5471.565993 Figure 3GC–MS/MS Chromatogram of Petroleum Ether extract of Canna indica. Table 4Phytochemicals Identified from GC–MS/MS Analysis of Petroleum Ether (PET) Extract of Canna IndicaS.NCompound NameRet. TimeConc. %m/zMS similarityFiguresKetone1Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1S)-7.2422.639597Alcohol2Z-10-Pentadecen-1-ol11.6711.68558532,4-Pentadien-1-ol, 3-pentyl-, (2Z)-16.9591.4183794Phytol18.4372.357197Terpene5Isoborneol7.4261.195956Caryophyllene10.120.9691957alpha.-Guaiene10.7710.98191798Epicurzerenone11.7495.48122889Curcumenol13.1922.6510576Ester10Dodecanoic acid, phenylmethyl ester29.1490.86577711Benzenepropanoic acid, 3.5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester30.6881.345783Hydrocarbon12Cyclopentane, 1,1,3,4-tetramethyl-, trans-3.5322.79558713Cyclohexane, 1,2,4-trimethyl-3.5751.58698514Cyclohexane, 1,2,4-trimethyl-3.7121.16699215Ethylbenzene3.7684.69919216Benzene, (2-iodoethyl)-3.86831.28928217Cyclopentene, 1-ethenyl-3-methylene-4.1426.05919418Nonane4.193.42579619Dodecane7.71.17579820Tetradecane9.7396.13579421Hexadecane11.5795.56579622Heneicosane13.8183.725797237-Heptadecene, 1-chloro-14.0131.19558324Cyclopropane, 2-(1,1-dimethyl-2-propenyl)-1,1-dimethyl-15.2351.39828425Heneicosane16.6752.33579726Heneicosane19.8791.445795Other279-Octadecenamide, (Z)-22.5471.565993 Phytochemicals Identified from GC–MS/MS Analysis of Petroleum Ether (PET) Extract of Canna Indica GC–MS/MS Chromatogram of Petroleum Ether extract of Canna indica. Phytochemicals Identified from GC–MS/MS Analysis of Ethyl Acetate Extract of Canna Indica Ethyl acetate extract resulted in the detection of 20 compounds and high abundance compounds were 9-Octadecenamide, (Z)- (30.57%), Sambucinol (27.37%), (-)-Spathulenol (6.92%), Biphenylene, 1,2,3,6,7,8,8a,8b-Octahydro-4,5-dimethyl- (5.02%), 1-Hydroxymethyl-7,7-dimethylbicyclo[2.2.1]heptan-2-one (4.57%) (Figure 4, Table 5). Table 5Phytochemicals Identified from GC–MS/MS Analysis of Ethyl Acetate (EA) Extract of Canna IndicaS/NCompound NameRet. TimeArea %m/zMS similarityFiguresAldehyde1Retinal13.7360.6769772D:A-Friedooleanan-28-al, 3-oxo-16.2931.6513775Alcohol3Glycerin5.3682.23618842,5,8,11,14,17-Hexaoxanonadecan-19-ol14.4850.6959665Sambucinol24.89227.3712466Ketones66-(1-Hydroxymethylvinyl)-4,8a-dimethyl-3,5,6,7,8,8a-hexahydro-1H-naphthalen-2-one16.491.4147807Bicyclo[5.1.0]octan-2-one, 4.6-diisopropylidene-8,8-dimethyl-18.7381.95163698Androst-5-en-3-one, 4.4-dimethyl-20.812.311247091-Hydroxymethyl-7,7-dimethylbicyclo[2.2.1]heptan-2-one26.4754.5715376Terpene10(-)-Spathulenol23.0936.928169Hydrocarbon11Nonadecanoic acid17.151.315577Others12Trehalose14.3891.587387133-Oxatricyclo[20.8.0.0(7,16)]triaconta-1(22),7(16),9,13,23,29-hexaene20.9291.041456514Biphenylene, 1,2,3,6,7,8,8a,8b-octahydro-4,5-dimethyl-21.6825.021887015Norgestrel23.651.391606416Androst-5-en-3-one, 4.4-dimethyl-23.7292.951246917Phenol, 2.4-bis(1-methyl-1-phenylethyl)-24.7751.13159018Methiocarb25.41521537219(4-isopropyl-cyclohex-1-en-3-on-1-yl) methyl glucopyranoside26.2883.2810873209-Octadecenamide, (Z)-29.0130.575991 Figure 4GC–MS/MS Chromatogram of Ethyl Acetate extract of Canna indica. Table 5Phytochemicals Identified from GC–MS/MS Analysis of Ethyl Acetate (EA) Extract of Canna IndicaS/NCompound NameRet. TimeArea %m/zMS similarityFiguresAldehyde1Retinal13.7360.6769772D:A-Friedooleanan-28-al, 3-oxo-16.2931.6513775Alcohol3Glycerin5.3682.23618842,5,8,11,14,17-Hexaoxanonadecan-19-ol14.4850.6959665Sambucinol24.89227.3712466Ketones66-(1-Hydroxymethylvinyl)-4,8a-dimethyl-3,5,6,7,8,8a-hexahydro-1H-naphthalen-2-one16.491.4147807Bicyclo[5.1.0]octan-2-one, 4.6-diisopropylidene-8,8-dimethyl-18.7381.95163698Androst-5-en-3-one, 4.4-dimethyl-20.812.311247091-Hydroxymethyl-7,7-dimethylbicyclo[2.2.1]heptan-2-one26.4754.5715376Terpene10(-)-Spathulenol23.0936.928169Hydrocarbon11Nonadecanoic acid17.151.315577Others12Trehalose14.3891.587387133-Oxatricyclo[20.8.0.0(7,16)]triaconta-1(22),7(16),9,13,23,29-hexaene20.9291.041456514Biphenylene, 1,2,3,6,7,8,8a,8b-octahydro-4,5-dimethyl-21.6825.021887015Norgestrel23.651.391606416Androst-5-en-3-one, 4.4-dimethyl-23.7292.951246917Phenol, 2.4-bis(1-methyl-1-phenylethyl)-24.7751.13159018Methiocarb25.41521537219(4-isopropyl-cyclohex-1-en-3-on-1-yl) methyl glucopyranoside26.2883.2810873209-Octadecenamide, (Z)-29.0130.575991 Phytochemicals Identified from GC–MS/MS Analysis of Ethyl Acetate (EA) Extract of Canna Indica GC–MS/MS Chromatogram of Ethyl Acetate extract of Canna indica. Antimicrobial Activity Antimicrobial activities of all partitions were evaluated against five gram-positive and eight gram-negative bacteria, with Azithromycin, Amoxicillin, Ciprofloxacin, and Fluconazole serving as reference standards for respective antimicrobial testing. The test samples exhibited a range of 6 mm to 18 mm in the zone of inhibition (ZOI), as outlined in Table 6. The aqueous fraction (AQSF) and dichloromethane fraction (DCMSF) displayed moderate antibacterial activity, particularly against E. coli (16.67 ± 0.47 mm for AQSF) and P. aeruginosa (17.67 ± 0.47 mm for AQSF). However, both ethyl acetate (EASF) and petroleum ether fractions (PESF) showed limited antibacterial efficacy, with mean inhibition zones generally below 12 mm across all bacterial strains. Notably, Gram-positive bacteria like S. aureus showed higher susceptibility to azithromycin (40.00 ± 0.82 mm) and ciprofloxacin (34.33 ± 0.94 mm) compared to the extracts, which demonstrated a maximum ZOI of 15 mm. Table 6The Antimicrobial Activity of Canna Indica Extracts and Standard Against Gram-Positive Bacteria and Gram-Negative BacteriaTest MicroorganismsZone of InhibitionAzithromycin (30 μg/disc)Amoxicillin (30 μg/disc)Ciprofloxacin (30 μg/disc)AQSF (100 μg/disc)DCMSF (100 μg/disc)EASF (100 μg/disc)PESF (100 μg/disc)Gram PositiveBacillus cereus33.67 ± 1.2533.00 ± 0.8231.33 ± 0.4715.00 ± 0.8211.00 ± 0.829.33 ± 0.477.33 ± 0.47Bacillus megaterium32.33 ± 2.0527.00 ± 0.8227.67 ± 0.4710.67 ± 0.949.67 ± 0.478.67 ± 0.47–Bacillus subtilis31.33 ± 1.2525.67 ± 1.7031.00 ± 0.828.33 ± 0.478.67 ± 0.47––Staphylococcus aureus40.00 ± 0.8235.33 ± 0.4734.33 ± 0.9414.33 ± 0.4713.00 ± 0.829.67 ± 0.477.67 ± 0.47Sarcina lutea37.67 ± 1.2533.00 ± 0.8228.00 ± 0.8213.67 ± 0.4710.00 ± 0.827.67 ± 0.476.33 ± 0.47Gram NegativeEscherichia coli37.67 ± 1.7035.67 ± 0.4731.00 ± 0.8216.67 ± 0.4712.33 ± 0.9411.33 ± 0.4711.67 ± 0.47Pseudomonas aeruginosa41.33 ± 0.4737.00 ± 0.8237.00 ± 0.8217.67 ± 0.4715.00 ± 0.829.67 ± 0.478.67 ± 0.47Salmonella paratyphi33.67 ± 1.7031.00 ± 0.8225.67 ± 0.9415.33 ± 0.4710.67 ± 0.479.33 ± 0.47–Salmonella typhi39.00 ± 0.8230.33 ± 1.2532.00 ± 0.8218.00 ± 0.8211.33 ± 0.47–6.33 ± 0.47Shigella dysenteriae35.67 ± 0.4731.33 ± 0.4734.00 ± 0.8216.33 ± 0.4712.33 ± 0.478.33 ± 0.477.67 ± 0.47Vibrio mimicus32.67 ± 1.2527.00 ± 0.8226.33 ± 0.4712.33 ± 0.479.33 ± 0.47––Vibrio parahemolyticus40.33 ± 0.4734.00 ± 0.8234.00 ± 0.8214.33 ± 0.4714.67 ± 0.476.33 ± 0.47– Table 6The Antimicrobial Activity of Canna Indica Extracts and Standard Against Gram-Positive Bacteria and Gram-Negative BacteriaTest MicroorganismsZone of InhibitionAzithromycin (30 μg/disc)Amoxicillin (30 μg/disc)Ciprofloxacin (30 μg/disc)AQSF (100 μg/disc)DCMSF (100 μg/disc)EASF (100 μg/disc)PESF (100 μg/disc)Gram PositiveBacillus cereus33.67 ± 1.2533.00 ± 0.8231.33 ± 0.4715.00 ± 0.8211.00 ± 0.829.33 ± 0.477.33 ± 0.47Bacillus megaterium32.33 ± 2.0527.00 ± 0.8227.67 ± 0.4710.67 ± 0.949.67 ± 0.478.67 ± 0.47–Bacillus subtilis31.33 ± 1.2525.67 ± 1.7031.00 ± 0.828.33 ± 0.478.67 ± 0.47––Staphylococcus aureus40.00 ± 0.8235.33 ± 0.4734.33 ± 0.9414.33 ± 0.4713.00 ± 0.829.67 ± 0.477.67 ± 0.47Sarcina lutea37.67 ± 1.2533.00 ± 0.8228.00 ± 0.8213.67 ± 0.4710.00 ± 0.827.67 ± 0.476.33 ± 0.47Gram NegativeEscherichia coli37.67 ± 1.7035.67 ± 0.4731.00 ± 0.8216.67 ± 0.4712.33 ± 0.9411.33 ± 0.4711.67 ± 0.47Pseudomonas aeruginosa41.33 ± 0.4737.00 ± 0.8237.00 ± 0.8217.67 ± 0.4715.00 ± 0.829.67 ± 0.478.67 ± 0.47Salmonella paratyphi33.67 ± 1.7031.00 ± 0.8225.67 ± 0.9415.33 ± 0.4710.67 ± 0.479.33 ± 0.47–Salmonella typhi39.00 ± 0.8230.33 ± 1.2532.00 ± 0.8218.00 ± 0.8211.33 ± 0.47–6.33 ± 0.47Shigella dysenteriae35.67 ± 0.4731.33 ± 0.4734.00 ± 0.8216.33 ± 0.4712.33 ± 0.478.33 ± 0.477.67 ± 0.47Vibrio mimicus32.67 ± 1.2527.00 ± 0.8226.33 ± 0.4712.33 ± 0.479.33 ± 0.47––Vibrio parahemolyticus40.33 ± 0.4734.00 ± 0.8234.00 ± 0.8214.33 ± 0.4714.67 ± 0.476.33 ± 0.47– The Antimicrobial Activity of Canna Indica Extracts and Standard Against Gram-Positive Bacteria and Gram-Negative Bacteria Cytotoxic Activity The EASF and DCMSF fractions revealed the lowest LC50 values at 1.11 and 1.21 µg/mL, respectively, in comparison to the standard of 0.451 µg/mL, the AQSF and PESF fractions displayed moderate cytotoxic activity with LC50 values of 25.47 and 15.52 µg/mL, respectively (Figure 5). Figure 5Cytotoxic effect of different fractions of leaves of Canna indica. Cytotoxic effect of different fractions of leaves of Canna indica. Analgesic Activity Figure 6 illustrated that highly significant (p< 0.001) analgesic activity was observed from most of the fractions of leaves of C. indica, while EASF showed very significant (p< 0.01). The highest reduction of writhing was observed for DCMSF, where 400 mg/kg dose reduced 53.57% writhing compared to the standard 81.34% reduction. Also, a dose-dependent effect was shown by all of these fractions. Figure 6Antidihreal and Analgesic activities of different fractions of leaves of Canna indica. Antidihreal and Analgesic activities of different fractions of leaves of Canna indica. Antidiarrheal Activity The various fractions of C. indica leaf extract illustrated a dose-dependent antidiarrheal effect. Notably, the DCMSF exhibited the most significant activity, with a 400 mg/kg dose resulting in a 45.21% reduction in diarrheal episodes compared to the standard loperamide, which achieved a 76.21% reduction. Additionally, the 400 mg/kg extracts of AQSF, PESF, and EASF displayed reductions of 40.5%, 26.21%, and 28.57%, respectively, in diarrhea incidence (Figure 6). Molecular Docking A comprehensive set of 103 compounds, originating from distinct fractions including DCM, AQ PET, and EA of the C. indica leaf extract, underwent meticulous computational docking studies. These investigations were conducted to assess the interactions and binding affinities of these compounds with five distinct receptors. The findings, including the detailed representation of binding affinities for each compound concerning the specified receptors, have been organized and presented in Table 7. Table 7The Identified Compounds from Leaves of Canna Indica with Their PubChem CID and Binding Affinity Scores Against Different ReceptorsExtractSerialCompoundsPubChem CidTargetsEGFRDHFRDORTNF-αCOX-2Aqueous13,3-Dimethoxy-2-butanone140871−4.7−4.2−4.7−4.4−4.52Butyl 6,9,12,15-octadecatetraenoate91697552−6.3−5.7−7.3−5.9−7.53Caryophyllene oxide1742210−7−6.6−7.5−7.4−6.44(R)-3,5,8a-Trimethyl-7,8,8a,9-tetrahydronaphtho[2,3-b]furan-4(6H)-one91711266−7.9−7.4−8.5−7.7−8.65Epicurzerenone5317062−6.5−6.1−7.4−6.6−7.66Isospathulenol102303030−7.7−6.8−8−7−6.771,3,6,10-Cyclotetradecatetraene, 3,7,11-trimethyl-14-(1-methylethyl)-, [S-(E,Z,E,E)]-6,436,662−7.6−7−9.1−8.7−6.48Curcumenol167812−8.3−6.8−8.1−7.7−6.49Cyclohexasiloxane, dodecamethyl-10911−1.7−1.4−1.6−1.2−1.510Danazol28417−8.4−8.6−8.1−9.1−711n-Propyl 5,8,11,14,17-eicosapentaenoate91697570−7.3−6.3−7.3−6.4−8.112Neophytadiene10446−6.7−5.7−6.3−5.8−7.2132-Pentadecanone, 6,10,14-trimethyl-10408−6.8−5.5−7−5.9−7.214Curcumenone153845−7.5−6.9−7.7−6.4−8151,4-Methanocycloocta[d]pyridazine, 1,4,4a,5,6,9,10,10a-octahydro-11,11-dimethyl-, (1.alpha.,4.alpha.,4a.alpha.,10a.alpha).-10,544,720−7−6.1−7.4−6.7−7.5161H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, [1ar-(1a.alpha.,4a.alpha.,7.beta.,7a.beta.,7b.alpha).]-6,432,640−7.2−7−7.5−7−6.417(1aR,4aS,8aS)-4a,8,8-Trimethyl-1,1a,4,4a,5,6,7,8-octahydrocyclopropa[d]naphthalene-2-carbaldehyde12444331−7.1−6.6−7.4−6.9−7.518Zederone101286196−7.2−7.2−7.9−7.4−6.219(1aR,3aS,7S,7aS,7bR)-1,1,3a,7-Tetramethyldecahydro-1H-cyclopropa[a]naphthalen-7-ol12309603−6.6−6.5−8.2−6.9−5.820Pseduosarsasapogenin-5,20-dien methyl ether552194−8.8−9.1−8.8−8.4−7.221alpha.-Chlorocyclooctanone oxime6505552−5.3−5.6−6.2−5.6−6.122Phytol5280435−6.9−5.5−6.6−5.8−7.323Norethindrone6230−7.1−7.9−8.5−8.4−6.824Decane, 1-bromo-2-methyl-545631−5.1−4.5−5.4−4.8−5.425Phytol, acetate6428538−7−5.9−7.3−6.3−7.5261-Oxaspiro[2.5]octan-4-one, 2,2,6-trimethyl-, cis-330109−5.8−5.8−6.7−5.8−6.9271-Pentanone,1-(1-[hydroxy(phenyl)methyl]cyclobutyl])557,977−6.7−6.1−7.4−6.9−7.228Corymbolone178931−7.5−6.9−7.9−6.9−6.42911.beta.-Hydroxyprogesterone101788−8.9−8.4−9.5−8.4−6.930Cycloprop[e]indene-1a,2(1H)-dimethanol, 3a,4,5,6,6a,6b-hexahydro-5,5,6b-trimethyl-, (1a.alpha.,3a.beta.,6a.beta.,6b.alpha).-(-)565,048−6.6−6.3−7.8−6.9−6.431Dodecane, 3-cyclohexyl-524423−6.9−5.5−6.8−5.6−7.3323-Buten-2-ol, 2-methyl-4-(1,3,3-trimethyl-7-oxabicyclo[4.1.0]hept-2-yl)-5,363,622−6.5−6.1−6.6−6.5−6.8331-Methyl-4-nitro-5-[(1,2-dimethyl-3-hydroxybutyl)amino]-(1H)-imidazole566702−5.8−5.7−6.9−6−6.9342-Methyltetracosane527459−6.3−5.2−6.5−5.3−7.1352,7-Octadiene, 1-butoxy-534461−5.5−4.6−5.4−4.8−5.636Acetic acid, 2-(2-acetoxy-2,5,5,8a-tetramethyldecalin-1-yl)-536,559−6.4−6.6−8.5−7.6−7.337Cholest-5-en-3-ol (3.beta).-, tetradecanoate313252−7−7.1−8.5−7.2−4.3Dichloromethane38Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1S)-2537−5−5−6.6−6−4.839Isoborneol6321405−5−5.3−6.6−5.8−4.640endo-Borneol6552009−4.8−5.1−6.6−6.1−4.741Cyclohexene, 4-pentyl-1-(4-propylcyclohexyl)-557,007−8.2−7−8.2−6.5−7.5421,1,4,7-Tetramethyldecahydro-1H-cyclopropa[e]azulene-4,7-diol178322−7−6.7−7−7.3−6.143(S,E)-4-Hydroxy-3,5,5-trimethyl-4-(3-oxobut-1-en-1-yl)cyclohex-2-enone688492−6.4−6.4−7−7.2−6.244(4R,4aR)-4,4a-Dimethyl-6-(prop-1-en-2-yl)-1,2,3,4,4a,7-hexahydronaphthalene90470826−7.6−6.7−8.3−7−7.2453,7,11,15-Tetramethyl-2-hexadecen-1-ol5366244−7−5.6−6.6−5.7−7.346Ergostane-3,5,6,12,25-pentol, 25-acetate, (3.beta.,5.alpha.,6.beta.,12.beta).-91,691,421−9.9−7.8−9.1−7.7−6.9472(1H)-Azulenone, 4,5,6,7,8,8a-hexahydro-8a-methyl-, (S)-22,216,158−6.2−6−7.4−6.2−6.748Aromadendrene oxide-(2)16,211,192−7.6−6.7−8.2−7−7.2493-Butoxy-1,1,1,7,7,7-hexamethyl-3,5,5-tris(trimethylsiloxy)tetrasiloxane553039−1.7−1.4−1.6−1.2−1.550Thunbergol5363523−5.7−6−7.6−8.1−5.2516-(1-Hydroxymethylvinyl)-4,8a-dimethyl-3,5,6,7,8,8a-hexahydro-1H-naphthalen-2-one564373−8−6.7−8.1−6.9−7.1522-Butenal, 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-5,369,997−6.7−5.9−7.6−6.6−7.3532-[4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl]cyclohex-1-en-1-carboxaldehyde5363101−9.2−7.7−9−7.5−6.754Octasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-hexadecamethyl-6329087−1.7−1.4−1.6−1.2−1.555Acetic acid, tricyclo[3.3.1.1(3,7)]decylidene-, ethyl ester600028−6.2−6.1−7.7−6.6−6.156(Chroman-7-yl)methylamine6424486−6.2−5.7−6.3−5.5−6.657Cyclononasiloxane, octadecamethyl-11172−1.7−1.4−1.6−1.2−1.5581-(4-Hydroxy-3-isopropenyl-4,7,7-trimethyl-cyclohept-1-enyl)-ethanone539314−6.2−6.5−7.5−7−7.559Dihydroartemisinin, 6-deshydro-5-deshydroxy-3-desoxy-541540−8.1−7.4−8.7−7.4−8.1604,7-Methanofuro[3,2-c]oxacycloundecin-6(4H)-one, 7,8,9,12-tetrahydro-3,11-dimethyl-5377116−7.5−7.2−8.3−8.2−761Biphenylene, 1,2,3,6,7,8,8a,8b-octahydro-4,5-dimethyl-583087−8−6.7−8−7.4−7.9629-Octadecenamide, (Z)-5,283,387−6.6−5.4−6.2−5.3−7.1631-Heptatriacotanol537071−5.8−5.3−6.7−5.3−6.364Eicosane8222−6−4.8−6.1−5.2−6.7651S,3R,4S,5R,6S-1-Hydroxy-2,2,3,4,5,6-hexamethyl-8-oxo-7,9-dioxatricyclo[4.2.1.0(3,5)]nonane539855−6.6−6.7−7.5−6.9−6.566Triacontane, 1-bromo-521082−5.8−5−6.5−5−6.4672,3:5,6-Di-O-1-Cyclohexylieden-1,4-cyclohexandiallylether15704917−7−7.4−8.3−8−6.66811-Methyltricosane530326−6.2−5.4−6.5−5.4−7.169Eicosyl isopropyl ether91691499−6.2−5.2−6.4−5.5−7Pet ether70Cyclopentane, 1,1,3,4-tetramethyl-, trans-6432224−5.5−5−5.8−5.1−5.471Cyclohexane, 1,2,4-trimethyl-91517−5.4−4.9−6−5−6.272Ethylbenzene7500−5.1−4.7−5.3−4.9−5.673Benzene, (2-iodoethyl)-28,503−5.2−4.8−5.4−4.8−5.874Cyclopentene, 1-ethenyl-3-methylene-562142−5.1−4.6−5.4−5−5.375Nonane8141−4.8−4.3−4.7−4.5−4.876Dodecane8182−5.2−4−5.3−4.6−5.577Tetradecane12389−5.6−4.5−5.4−4.6−5.978Caryophyllene5281515−7.1−6.8−7.5−7−6.779alpha.-Guaiene6429358−7.8−6−7.5−7.3−7.380Hexadecane11006−5.8−4.5−5.6−4.7−6.481Z-10-Pentadecen-1-ol5364483−6.1−5.2−6−5−6.282Heneicosane12403−6.1−4.8−6.4−5−6.7837-Heptadecene, 1-chloro-5364485−6−5.5−5.8−4.9−6.684Cyclopropane, 2-(1,1-dimethyl-2-propenyl)-1,1-dimethyl-557547−5−4.4−5.9−4.9−5.8852,4-Pentadien-1-ol, 3-pentyl-, (2Z)-5,367,717−5.2−4.6−5.7−5.2−5.386Dodecanoic acid, phenylmethyl ester8791−7−5.7−7.1−6.1−7.287Benzenepropanoic acid, 3.5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester16386−7.3−6.8−9−6.8−8.7Ethyl Acetate88Glycerin753−4.3−3.3−4.1−3.5−3.889Retinal638015−9−7−8.4−7.1−6.490Trehalose7427−5.9−7.2−7.4−6.1−5.7912,5,8,11,14,17-Hexaoxanonadecan-19-ol90207−4.9−4.6−5.2−4.2−5.492D:A-Friedooleanan-28-al, 3-oxo-586214−9.8−8.4−8.6−9.5−7.693Nonadecanoic acid12591−6.4−5.2−6.1−5.5−794Bicyclo[5.1.0]octan-2-one, 4.6-diisopropylidene-8,8-dimethyl-534691−7.9−7.4−7.8−7.3−7.595Androst-5-en-3-one, 4.4-dimethyl-22216284−8.5−8.7−10.1−8.2−7.3963-Oxatricyclo[20.8.0.0(7,16)]triaconta-1(22),7(16),9,13,23,29-hexaene5368332−7.8−7−9.8−9.8−7.797(-)-Spathulenol13854255−7.8−6.9−8.4−7.2−7.398Norgestrel13109−7.9−9−8.7−8.3−6.599Phenol, 2.4-bis(1-methyl-1-phenylethyl)-76,013−9.8−8−9.5−8.7−9.2100Sambucinol5459101−7.3−6.6−8.2−7.4−6101Methiocarb16248−6.5−6.4−6.5−5.7−7102(4-isopropyl-cyclohex-1-en-3-on-1-yl) methyl glucopyranoside91704271−7.6−7.4−8.8−6.8−7.21031-Hydroxymethyl-7,7-dimethylbicyclo[2.2.1]heptan-2-one572679−5.3−5.1−6.7−6.2−4.7StandardLapatinib208908−10.8––––Ciprofloxacin2764–−8.2–––Glibenclamide3488––−10.2––Diclofenac3033–––−7.1− 7.9 Table 7The Identified Compounds from Leaves of Canna Indica with Their PubChem CID and Binding Affinity Scores Against Different ReceptorsExtractSerialCompoundsPubChem CidTargetsEGFRDHFRDORTNF-αCOX-2Aqueous13,3-Dimethoxy-2-butanone140871−4.7−4.2−4.7−4.4−4.52Butyl 6,9,12,15-octadecatetraenoate91697552−6.3−5.7−7.3−5.9−7.53Caryophyllene oxide1742210−7−6.6−7.5−7.4−6.44(R)-3,5,8a-Trimethyl-7,8,8a,9-tetrahydronaphtho[2,3-b]furan-4(6H)-one91711266−7.9−7.4−8.5−7.7−8.65Epicurzerenone5317062−6.5−6.1−7.4−6.6−7.66Isospathulenol102303030−7.7−6.8−8−7−6.771,3,6,10-Cyclotetradecatetraene, 3,7,11-trimethyl-14-(1-methylethyl)-, [S-(E,Z,E,E)]-6,436,662−7.6−7−9.1−8.7−6.48Curcumenol167812−8.3−6.8−8.1−7.7−6.49Cyclohexasiloxane, dodecamethyl-10911−1.7−1.4−1.6−1.2−1.510Danazol28417−8.4−8.6−8.1−9.1−711n-Propyl 5,8,11,14,17-eicosapentaenoate91697570−7.3−6.3−7.3−6.4−8.112Neophytadiene10446−6.7−5.7−6.3−5.8−7.2132-Pentadecanone, 6,10,14-trimethyl-10408−6.8−5.5−7−5.9−7.214Curcumenone153845−7.5−6.9−7.7−6.4−8151,4-Methanocycloocta[d]pyridazine, 1,4,4a,5,6,9,10,10a-octahydro-11,11-dimethyl-, (1.alpha.,4.alpha.,4a.alpha.,10a.alpha).-10,544,720−7−6.1−7.4−6.7−7.5161H-Cycloprop[e]azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, [1ar-(1a.alpha.,4a.alpha.,7.beta.,7a.beta.,7b.alpha).]-6,432,640−7.2−7−7.5−7−6.417(1aR,4aS,8aS)-4a,8,8-Trimethyl-1,1a,4,4a,5,6,7,8-octahydrocyclopropa[d]naphthalene-2-carbaldehyde12444331−7.1−6.6−7.4−6.9−7.518Zederone101286196−7.2−7.2−7.9−7.4−6.219(1aR,3aS,7S,7aS,7bR)-1,1,3a,7-Tetramethyldecahydro-1H-cyclopropa[a]naphthalen-7-ol12309603−6.6−6.5−8.2−6.9−5.820Pseduosarsasapogenin-5,20-dien methyl ether552194−8.8−9.1−8.8−8.4−7.221alpha.-Chlorocyclooctanone oxime6505552−5.3−5.6−6.2−5.6−6.122Phytol5280435−6.9−5.5−6.6−5.8−7.323Norethindrone6230−7.1−7.9−8.5−8.4−6.824Decane, 1-bromo-2-methyl-545631−5.1−4.5−5.4−4.8−5.425Phytol, acetate6428538−7−5.9−7.3−6.3−7.5261-Oxaspiro[2.5]octan-4-one, 2,2,6-trimethyl-, cis-330109−5.8−5.8−6.7−5.8−6.9271-Pentanone,1-(1-[hydroxy(phenyl)methyl]cyclobutyl])557,977−6.7−6.1−7.4−6.9−7.228Corymbolone178931−7.5−6.9−7.9−6.9−6.42911.beta.-Hydroxyprogesterone101788−8.9−8.4−9.5−8.4−6.930Cycloprop[e]indene-1a,2(1H)-dimethanol, 3a,4,5,6,6a,6b-hexahydro-5,5,6b-trimethyl-, (1a.alpha.,3a.beta.,6a.beta.,6b.alpha).-(-)565,048−6.6−6.3−7.8−6.9−6.431Dodecane, 3-cyclohexyl-524423−6.9−5.5−6.8−5.6−7.3323-Buten-2-ol, 2-methyl-4-(1,3,3-trimethyl-7-oxabicyclo[4.1.0]hept-2-yl)-5,363,622−6.5−6.1−6.6−6.5−6.8331-Methyl-4-nitro-5-[(1,2-dimethyl-3-hydroxybutyl)amino]-(1H)-imidazole566702−5.8−5.7−6.9−6−6.9342-Methyltetracosane527459−6.3−5.2−6.5−5.3−7.1352,7-Octadiene, 1-butoxy-534461−5.5−4.6−5.4−4.8−5.636Acetic acid, 2-(2-acetoxy-2,5,5,8a-tetramethyldecalin-1-yl)-536,559−6.4−6.6−8.5−7.6−7.337Cholest-5-en-3-ol (3.beta).-, tetradecanoate313252−7−7.1−8.5−7.2−4.3Dichloromethane38Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1S)-2537−5−5−6.6−6−4.839Isoborneol6321405−5−5.3−6.6−5.8−4.640endo-Borneol6552009−4.8−5.1−6.6−6.1−4.741Cyclohexene, 4-pentyl-1-(4-propylcyclohexyl)-557,007−8.2−7−8.2−6.5−7.5421,1,4,7-Tetramethyldecahydro-1H-cyclopropa[e]azulene-4,7-diol178322−7−6.7−7−7.3−6.143(S,E)-4-Hydroxy-3,5,5-trimethyl-4-(3-oxobut-1-en-1-yl)cyclohex-2-enone688492−6.4−6.4−7−7.2−6.244(4R,4aR)-4,4a-Dimethyl-6-(prop-1-en-2-yl)-1,2,3,4,4a,7-hexahydronaphthalene90470826−7.6−6.7−8.3−7−7.2453,7,11,15-Tetramethyl-2-hexadecen-1-ol5366244−7−5.6−6.6−5.7−7.346Ergostane-3,5,6,12,25-pentol, 25-acetate, (3.beta.,5.alpha.,6.beta.,12.beta).-91,691,421−9.9−7.8−9.1−7.7−6.9472(1H)-Azulenone, 4,5,6,7,8,8a-hexahydro-8a-methyl-, (S)-22,216,158−6.2−6−7.4−6.2−6.748Aromadendrene oxide-(2)16,211,192−7.6−6.7−8.2−7−7.2493-Butoxy-1,1,1,7,7,7-hexamethyl-3,5,5-tris(trimethylsiloxy)tetrasiloxane553039−1.7−1.4−1.6−1.2−1.550Thunbergol5363523−5.7−6−7.6−8.1−5.2516-(1-Hydroxymethylvinyl)-4,8a-dimethyl-3,5,6,7,8,8a-hexahydro-1H-naphthalen-2-one564373−8−6.7−8.1−6.9−7.1522-Butenal, 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-5,369,997−6.7−5.9−7.6−6.6−7.3532-[4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hexa-1,3,5-trienyl]cyclohex-1-en-1-carboxaldehyde5363101−9.2−7.7−9−7.5−6.754Octasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13,15,15-hexadecamethyl-6329087−1.7−1.4−1.6−1.2−1.555Acetic acid, tricyclo[3.3.1.1(3,7)]decylidene-, ethyl ester600028−6.2−6.1−7.7−6.6−6.156(Chroman-7-yl)methylamine6424486−6.2−5.7−6.3−5.5−6.657Cyclononasiloxane, octadecamethyl-11172−1.7−1.4−1.6−1.2−1.5581-(4-Hydroxy-3-isopropenyl-4,7,7-trimethyl-cyclohept-1-enyl)-ethanone539314−6.2−6.5−7.5−7−7.559Dihydroartemisinin, 6-deshydro-5-deshydroxy-3-desoxy-541540−8.1−7.4−8.7−7.4−8.1604,7-Methanofuro[3,2-c]oxacycloundecin-6(4H)-one, 7,8,9,12-tetrahydro-3,11-dimethyl-5377116−7.5−7.2−8.3−8.2−761Biphenylene, 1,2,3,6,7,8,8a,8b-octahydro-4,5-dimethyl-583087−8−6.7−8−7.4−7.9629-Octadecenamide, (Z)-5,283,387−6.6−5.4−6.2−5.3−7.1631-Heptatriacotanol537071−5.8−5.3−6.7−5.3−6.364Eicosane8222−6−4.8−6.1−5.2−6.7651S,3R,4S,5R,6S-1-Hydroxy-2,2,3,4,5,6-hexamethyl-8-oxo-7,9-dioxatricyclo[4.2.1.0(3,5)]nonane539855−6.6−6.7−7.5−6.9−6.566Triacontane, 1-bromo-521082−5.8−5−6.5−5−6.4672,3:5,6-Di-O-1-Cyclohexylieden-1,4-cyclohexandiallylether15704917−7−7.4−8.3−8−6.66811-Methyltricosane530326−6.2−5.4−6.5−5.4−7.169Eicosyl isopropyl ether91691499−6.2−5.2−6.4−5.5−7Pet ether70Cyclopentane, 1,1,3,4-tetramethyl-, trans-6432224−5.5−5−5.8−5.1−5.471Cyclohexane, 1,2,4-trimethyl-91517−5.4−4.9−6−5−6.272Ethylbenzene7500−5.1−4.7−5.3−4.9−5.673Benzene, (2-iodoethyl)-28,503−5.2−4.8−5.4−4.8−5.874Cyclopentene, 1-ethenyl-3-methylene-562142−5.1−4.6−5.4−5−5.375Nonane8141−4.8−4.3−4.7−4.5−4.876Dodecane8182−5.2−4−5.3−4.6−5.577Tetradecane12389−5.6−4.5−5.4−4.6−5.978Caryophyllene5281515−7.1−6.8−7.5−7−6.779alpha.-Guaiene6429358−7.8−6−7.5−7.3−7.380Hexadecane11006−5.8−4.5−5.6−4.7−6.481Z-10-Pentadecen-1-ol5364483−6.1−5.2−6−5−6.282Heneicosane12403−6.1−4.8−6.4−5−6.7837-Heptadecene, 1-chloro-5364485−6−5.5−5.8−4.9−6.684Cyclopropane, 2-(1,1-dimethyl-2-propenyl)-1,1-dimethyl-557547−5−4.4−5.9−4.9−5.8852,4-Pentadien-1-ol, 3-pentyl-, (2Z)-5,367,717−5.2−4.6−5.7−5.2−5.386Dodecanoic acid, phenylmethyl ester8791−7−5.7−7.1−6.1−7.287Benzenepropanoic acid, 3.5-bis(1,1-dimethylethyl)-4-hydroxy-, octadecyl ester16386−7.3−6.8−9−6.8−8.7Ethyl Acetate88Glycerin753−4.3−3.3−4.1−3.5−3.889Retinal638015−9−7−8.4−7.1−6.490Trehalose7427−5.9−7.2−7.4−6.1−5.7912,5,8,11,14,17-Hexaoxanonadecan-19-ol90207−4.9−4.6−5.2−4.2−5.492D:A-Friedooleanan-28-al, 3-oxo-586214−9.8−8.4−8.6−9.5−7.693Nonadecanoic acid12591−6.4−5.2−6.1−5.5−794Bicyclo[5.1.0]octan-2-one, 4.6-diisopropylidene-8,8-dimethyl-534691−7.9−7.4−7.8−7.3−7.595Androst-5-en-3-one, 4.4-dimethyl-22216284−8.5−8.7−10.1−8.2−7.3963-Oxatricyclo[20.8.0.0(7,16)]triaconta-1(22),7(16),9,13,23,29-hexaene5368332−7.8−7−9.8−9.8−7.797(-)-Spathulenol13854255−7.8−6.9−8.4−7.2−7.398Norgestrel13109−7.9−9−8.7−8.3−6.599Phenol, 2.4-bis(1-methyl-1-phenylethyl)-76,013−9.8−8−9.5−8.7−9.2100Sambucinol5459101−7.3−6.6−8.2−7.4−6101Methiocarb16248−6.5−6.4−6.5−5.7−7102(4-isopropyl-cyclohex-1-en-3-on-1-yl) methyl glucopyranoside91704271−7.6−7.4−8.8−6.8−7.21031-Hydroxymethyl-7,7-dimethylbicyclo[2.2.1]heptan-2-one572679−5.3−5.1−6.7−6.2−4.7StandardLapatinib208908−10.8––––Ciprofloxacin2764–−8.2–––Glibenclamide3488––−10.2––Diclofenac3033–––−7.1− 7.9 The Identified Compounds from Leaves of Canna Indica with Their PubChem CID and Binding Affinity Scores Against Different Receptors Compound C46 demonstrated the highest affinity towards EGFR, with a binding score of −9.9 kcal/mol, albeit slightly lower than the standard Lapatinib, with a score of −10.8 kcal/mol. Following closely were C92 and C99, both recording a binding score of −9.8 kcal/mol, trailed by C53 and C89 with scores of −9.2 kcal/mol and −9 kcal/mol, respectively. Notably, nine of these compounds exhibited binding scores lower than −8 kcal/mol, and an additional 30 compounds recorded scores lower than −7 kcal/mol. For DHFR, the lowermost affinity was noted for C29, displaying a binding affinity value of −9.1 kcal/mol. Furthermore, C98, C95, C10, C29, and C92 showcased notable binding affinities toward DHFR, scoring −9, −8.7, −8.6, −8.4, and −8.4 kcal/mol, respectively. Notably, these values surpassed the standard ciprofloxacin affinity of −8.2 kcal/mol. In the case of DOR, C95 exhibited the lowest affinity score of −10.1 kcal/mol, slightly trailing behind Loperamide with a score of −10.2 kcal/mol. Additionally, C96, C29, C99, C7, C46, C53, and C87 demonstrated binding scores of −9.8, −9.5, −9.5, −9.1, −9.1, −9, and −9 kcal/mol, respectively. Notably, 23 compounds displayed binding affinities lower than −8 kcal/mol. The most substantial binding affinity against TNF-α was documented for C96, boasting an affinity value of −9.8 kcal/mol, followed by C92 and C10 with scores of −9.5 and −9.1 kcal/mol, respectively. Several compounds surpassed the affinity score of the standard Diclofenac. Notably, C7 and C99 recorded −8.7 kcal/mol, while C20, C23, and C29 achieved −8.4 kcal/mol. Additionally, C60 and C95 exhibited affinity scores of −8.2 kcal/mol. Lastly, C99 demonstrated the most robust binding affinity against COX-2, registering a binding score of −9.2 kcal/mol. Notably, C87, C4, C11, C59, and C14 displayed substantial binding affinities of −8.7, −8.6, −8.1, −8.1, and −8 kcal/mol, respectively, surpassing the standard Diclofenac value of −7.9 kcal/mol. Discussion The quest for novel bioactive compounds applicable in emerging therapies highlights the prominence of medicinal plants. In developing nations, there is a growing focus on extensively utilizing plant-based remedies due to their multifaceted protective benefits and positive impact on human health, with traditional medicines being relied upon by approximately 80% of individuals, even in underdeveloped regions.40,59 These medicinal plant extracts, intricate combinations of secondary metabolites from plants, animals, and microorganisms, typically contain 10 to 60 ingredients in varying concentrations, often relying on 2–4 key molecules for their biological features.60,61 The exploration of the chemical composition and structure of these extracts unveils diverse biological potentials. The DCM extract of C. indica yields 1-Heptatriacotanol, a compound exhibiting potent anti-hypercholesterolemic properties.62 Oleamide, also known as 9-Octadecenamide, emerges as a versatile pharmacological candidate with capabilities such as sleep induction, hypomotility, and hypothermia.63,64 Furthermore, Oleamide contributes to vasodilation and acts as a hypolipidemic agent, reducing serum triglycerides, total cholesterol, low-density lipoprotein cholesterol, and hepatic triglycerides.65 Aromadendrene oxide 2 (AO-(2)) showcases anti-cancer potential against skin epidermoid cancer.66 Curcumenol demonstrates efficacy against various cancers, particularly lung cancer, by inducing cell death and suppressing proliferation through the ferroptotic pathway.67 It also inhibits the expression of the cervical cancer oncogene YWHAG.68 In rats with chronic renal failure, Curcumenol improves renal function by suppressing inflammation and modulating the SIRT1 and NF-κB signaling pathways.69 Additionally, Curcumenol exhibits a protective effect against intervertebral disc degeneration (IVDD) due to its anti-inflammatory activity.70 Phytol, a medically significant compound, boasts diverse biological activities, including anti-anxiety, metabolism modulation, cytotoxicity, antioxidant properties, autophagy- and apoptosis-inducing effects, antinociception, anti-inflammatory action, immune modulation, and antimicrobial activity.71 Neophytadiene is reported to have neurological effects, acting against anxiety and epilepsy.72 Curcumenone, a sesquiterpene, demonstrates vasorelaxant and hepatoprotective activity and can prevent alcohol-induced intoxication.73 Caryophyllene oxide exhibits notable analgesic and anti-inflammatory effects and possesses anticancer properties, making it a potential complementary medicine alongside conventional therapy.74,75 Tetradecane shows antimicrobial and antifungal activity.76 Isoborneol is reported to have cardioprotective effects and antiviral properties.77,78 Heneicosane is a potent antimicrobial agent.79 Caryophyllene, a bioactive sesquiterpene, is effective in reducing inflammation and alleviating various neurodegenerative diseases, as well as demonstrating antimicrobial, anticonvulsant, analgesic, myorelaxant, sedative, and anti-depressive properties.80 Spathulenol is reported to exhibit neuroprotective activity, being effective against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y neuroblastoma cells.80 In another study, Spathulenol demonstrates significant antimycobacterial activity against Mycobacterium tuberculosis strains, including a resistant strain.81 Cytotoxicity assays, commonly utilizing brine shrimp as a zoological specimen, are frequently employed to evaluate the presence of cytotoxic compounds in plant material. The cytotoxic properties of terrestrial plants have been extensively studied through this method, as evidenced in various research studies.82 This investigation found the potentiality of the plant extricates cytotoxic efficacy against brine shrimp. The results shown in Figure 5 indicate that the EASF and DCMSF fractions exhibited the highest cytotoxic activity, with LC50 values of 1.11 and 1.21 µg/mL, respectively. These values are significantly lower compared to the standard (Vincristine), which has an LC50 value of 0.451 µg/mL. In contrast, the AQSF and PESF fractions showed moderate cytotoxic activity. This suggests that while EASF and DCMSF are highly potent, AQSF and PESF have a less pronounced cytotoxic effect. Adding comparative data from the literature on C. indica highlights the strength of our findings, as dichloromethane and ethanol extracts of C. indica leaves exhibited significantly higher LC50 values of 273.9 µg/mL (167.8–447.0 µg/mL) and >1000 µg/mL, respectively, underscoring the exceptional efficacy of our EASF and DCMSF fractions.83 These differences underscore the influence of solvent choice on the extraction of bioactive compounds, as certain solvents may selectively isolate compounds with heightened cytotoxic activity. However, it is essential to recognize that while the brine shrimp lethality assay provides a quick and cost-effective measure of toxicity, it serves as a preliminary indicator rather than a definitive predictor of anticancer potential in human cells. Therefore, further bioassay-guided fractionation and testing on human cell lines are recommended to isolate specific bioactive compounds and verify the therapeutic relevance of these extracts, allowing for a more comprehensive understanding of the plant’s medicinal potential. Bacteria possess an innate genetic inclination to build resistance, underscoring the imperative for continuously advancing novel antimicrobial medications to counteract a broad spectrum of microorganisms.84 These antimicrobials selectively affect several mechanisms, including inhibiting microbial cell wall construction, altering crucial enzymatic pathways, and impeding the generation of genetic materials and proteins.85,86 In this study, the antimicrobial activity of different fractions (AQSF, DCMSF, EASF, PESF) was evaluated against various Gram-positive and Gram-negative bacteria, and compared with standard antibiotics (Azithromycin, Amoxicillin, Ciprofloxacin) (Table 6). The standard antibiotics demonstrated significant inhibition zones across all tested microorganisms, ranging from 25 to 42 mm. Among the fractions, AQSF exhibited the highest activity, with inhibition zones between 8 to 18 mm, showing relatively better efficacy against Gram-negative bacteria. DCMSF, EASF, and PESF displayed lower antimicrobial activity, with inhibition zones ranging from 8 to 15 mm, 6 to 14 mm, and 6 to 12 mm, respectively. In another research illustrates the antibacterial potential of its methanolic and ethyl acetate extracts against three bacteria. Methanolic extracts of C. indica leaves and flowers demonstrated activity against Bacillus subtilis, and ethyl acetate extracts of flowers and stems/barks also inhibited B. subtilis. However, hexane and distilled water extracts from various parts showed no antibacterial effects, indicating that solvent choice significantly affects the extraction of active compounds. Additionally, oil extracts of C. indica displayed notable activity against S. aureus but limited action against B. subtilis, which aligns with our findings that certain fractions, like AQSF, exhibit more promising antimicrobial activity than others.87 These comparisons underscore that while the tested plant fractions in our study display potential antimicrobial activity, particularly AQSF. However, their efficacy is lower than that of standard antibiotics. Furthermore, solvent selection appears to play a crucial role in extracting bioactive components with antibacterial properties. Given the relatively moderate antibacterial activity of these fractions, further isolation of bioactive compounds and testing against resistant strains is recommended. This approach could potentially identify novel compounds with more potent antimicrobial effects, addressing the urgent need for effective alternatives to conventional antibiotics in combating resistant bacteria. The study also demonstrates the dose-dependent antidiarrheal effects of tested plant extracts, notably observed compared to loperamide, a standard antidiarrheal drug. Upon ingesting castor oil, ricinoleic acid is released into the intestinal lumen, causing irritation and inflammation in the mucosa. This process hinders the re-absorption of Na+, K+, and water, triggering the release of inflammatory mediators like prostaglandins, histamine, and nitric oxide.8,88 In castor oil-induced diarrhea, the extract, particularly DCMSF and AQSF, exhibits significant inhibition of diarrheal faces, which could be by blicking release of Ricinoleic acid. Acetic acid exhibits a significant peripheral antinociceptive effect, with the writhing experiment indicating its impact on both central and peripheral analgesic drug activity linked to arachidonic acid synthesis inhibition.89 Pain may arise from the release of substances like serotonin and bradykinin, affecting damaged peripheral neurons sensitive to opioids and non-steroids.90 Intraperitoneal acetic acid injection activates chemosensitive nociceptors, causing visceral inflammation with histamine, prostaglandins, serotonin, and bradykinin secretion.91 In our experiment, different fractions of C. indica showed potential efficacy in pain management by reduction of writhing. Specially DCMSF and PESF exhibited the highest activities. Comparatively, these findings underscore the potential of these fractions for pain relief applications; however, they remain less effective than standard analgesics. Further comparative studies could help understand their exact mechanistic pathways in pain modulation, especially when targeting opioid and non-steroidal pathways. Evidence reveals that elevated EGFR levels in gastric cancer, when co-expressed with ligands like EGF, are linked to poor overall survival. In breast cancer, increased EGFR expression is associated with reduced patient survival, advanced clinical stage, and resistance to endocrine therapy. The role of EGFR in colorectal cancer is less clear but is linked to tumor grade, stage, and survival, albeit to a lesser extent than in other cancers. Overall, the EGFR signaling pathway remains significant in these tumors, indicating its prognostic relevance.92 The analysis of the compounds revealed that various types of bonding interactions play critical roles in determining bioactivity. For instance, alkyl bonds contribute to the lipophilicity of the compounds, enhancing their ability to penetrate cellular membranes and thereby increasing their bioavailability.93 Additionally, pi-pi interactions are significant as they can stabilize the binding of ligands to their target receptors, facilitating effective molecular recognition and enhancing biological activity. These interactions not only improve the affinity of compounds for their targets but also influence the pharmacokinetic properties, which are essential for therapeutic efficacy.94 Our investigation uncovers the capability of the identified phytochemicals to bind with EGFR, providing insights into their potential. Notably, C46 exhibits the lowest binding affinity to EGFR, forming three conventional hydrogen bonds, one unfavorable acceptor-acceptor bond, and nine alkyl bonds (Table 8, Figure 7). In contrast, C92 and C99 demonstrate significant binding affinity to the receptor. C92 establishes two conventional hydrogen bonds, one carbon-hydrogen bond, and three alkyl bonds, while C99 forms one pi-carbon bond, three pi-sigma bonds, and three alkyl bonds. Comparably, Lapatinib interacted with the receptor through six different bond types and showed a binding affinity of −10.9 kcal/mol. Table 8Bond and Binding Site of Highly Active Compounds Against Different Targets Including EGFR, DGFR, DOR, TNF-α, and COX-2ReceptorCompoundsBinding Affinities (kcal/mol)Bond TypeAmino acidsEGFRC46−9.9Conventional Hydrogen BondSer 720, Thr 854, Asp 855Unfavorable Acceptor- AcceptorAsn 842AlkylLeu 718, Val 726, Ala 743, Lys 745, Leu 777, Leu 788, Cys 797, Leu 844, Leu 858C53−9.2Conventional Hydrogen BondTyr 998Carbon Hydrogen BondPhe 795AlkylLeu 718, Val 726, Ala 743, Leu 792, Cys 797, Leu 844, Leu 1001C89−9Conventional Hydrogen BondMet 766AlkylLeu 718, Val 726, Ala 743, Leu 777, Leu 788, Leu 792, Met 793, Cys 797, Leu 844.C92−9.8Conventional Hydrogen BondCys 797, Thr 854Carbon Hydrogen BondAsp 800AlkylVal 726, Arg 841, Leu 844C99−9.8Pi- CarbonLys 745Pi- SigmaLeu 718, Val 726, Leu 844AlkylAla 743, Leu 788, Cys 797Lapatinib−10.8Conventional Hydrogen BondLys 745, Thr 790Carbon Hydrogen BondSer 720AlkylLeu 718, Val 726, Ala A: 743, Leu 844Pi- SigmaMet 766Pi-Pi T-shapedPhe 856Halogen(Fluorine)Cys 775, Arg 776DHFRC10−8.6Carbon Hydrogen BondTyr 121AlkylLeu 22, Lys 55C20−9.1Carbon Hydrogen BondAla 9AlkylLeu 22,Phe 34, Lys 55C29−8.4Carbon Hydrogen BondSer 118AlkylIle 16, Leu 22C92−8.4Conventional Hydrogen BondGly 20AlkylLys 55C95−8.7AlkylIle 16, Leu 22C98−9Conventional Hydrogen BondAla 9Carbon Hydrogen BondVal 8AlkylIle 16, Leu 22, Lys 55Ciprofloxacin−8.2Conventional Hydrogen BondAla 9Carbon Hydrogen BondVal 8, Thr 56, Ser 118AlkylIle 16, Leu 22, Lys 55DORC29−9.5AlkylVal 316, Ala 319, Phe 329C46−9.1Unfavorable Donor-DonorArg 76AlkylVal 68, Leu 69Pi- SigmaPhe 72C95−10.1AlkylVal 62, Leu 69, Val 70, Pro 315, Val 316, Ala 319, Phe 329C96−9.8AlkylMet 71, Val 75C99−9.5Pi- SigmaLeu 69Pi- Pi StackedPhe 329AlkylVal 62, Val 70, Pro 315, Val 316,Ala 319, Leu 332Loperamide−10.2Conventional Hydrogen BondLeu 69AlkylVal 70, Ala 319, Phe 325, Cys 328, Leu 332Pi -Pi StackedPhe 72TNF-alphaC7−8.7Pi- SigmaTyr 59AlkylLeu 57, Tyr 59, Tyr 151C10−9.1Conventional Hydrogen BondSer 60Pi- SigmaTyr 59AlkylLeu 57, Tyr 59, Tyr 151C92−9.5Pi- SigmaTyr 59AlkylTyr 59, Tyr 119, Tyr 151C96−9.8Carbon Hydrogen BondGly 121AlkylAla 96C99−8.7Pi- Pi StackedTyr 59, Tyr 119, Tyr 119AlkylLeu 57Diclofenac−7.1Conventional Hydrogen BondLeu 120Pi- Pi StackedTyr 59, Tyr 119COX-2C4−8.6Carbon Hydrogen BondVal 523,Ser 530Pi- Pi StackedPhe 518, Gly 526AlkylVal 349, Leu 352, Tyr 385, Trp 387, Ala 527, Leu 531C11−8.1AlkylHis 90, Val 116, Val 349, Leu 352, Leu 359, Tyr 385, Trp 387,Ala 516, Met 522, Val 523, Ala 527, Leu 531C14−8Conventional Hydrogen BondSer 530AlkylVal 349, Leu 352, Tyr 385, Trp 387, Phe 518, Met 522, Ala 527C59−8.1AlkylTyr 348, Val 349, Leu 352, Leu 384, Tyr 385, Trp 387, Phe 518, Met 522, Val 523, Ala 527C87−8.7Van der WaalsAla 516Pi- SigmaThr 94Amide -Pi StackedAsp 515AlkylVal 116, Val 349, Leu 352, Leu 359, Tyr 385, Trp 387, Pro 514, Phe 518, Val 523, Ala 527, Leu 531,C99−9.2Pi- SigmaVal 349, Val 523, Ala 527Pi- Pi T -shapedTrp 387AlkylTyr 348, Leu 352, Tyr 355Pi- sulfurMet 522Diclofenac−7.9Conventional Hydrogen BondTyr 355Pi- SigmaVal 349, Ala 527Amide -Pi StackedGly 526AlkylLeu 352, Leu 531 Figure 7Molecular Interactions of Phytochemicals with EGFR enzyme with the most prominent phytocompounds, here (A) interactions of Compound 46 and EGFR enzyme, (B) interactions of Compound 53 and EGFR enzyme, (C) interactions of Compound 92 and EGFR enzyme, (D) interactions of Compound 95 and EGFR enzyme, (E) interactions of standard Lapatinib and EGFR. Table 8Bond and Binding Site of Highly Active Compounds Against Different Targets Including EGFR, DGFR, DOR, TNF-α, and COX-2ReceptorCompoundsBinding Affinities (kcal/mol)Bond TypeAmino acidsEGFRC46−9.9Conventional Hydrogen BondSer 720, Thr 854, Asp 855Unfavorable Acceptor- AcceptorAsn 842AlkylLeu 718, Val 726, Ala 743, Lys 745, Leu 777, Leu 788, Cys 797, Leu 844, Leu 858C53−9.2Conventional Hydrogen BondTyr 998Carbon Hydrogen BondPhe 795AlkylLeu 718, Val 726, Ala 743, Leu 792, Cys 797, Leu 844, Leu 1001C89−9Conventional Hydrogen BondMet 766AlkylLeu 718, Val 726, Ala 743, Leu 777, Leu 788, Leu 792, Met 793, Cys 797, Leu 844.C92−9.8Conventional Hydrogen BondCys 797, Thr 854Carbon Hydrogen BondAsp 800AlkylVal 726, Arg 841, Leu 844C99−9.8Pi- CarbonLys 745Pi- SigmaLeu 718, Val 726, Leu 844AlkylAla 743, Leu 788, Cys 797Lapatinib−10.8Conventional Hydrogen BondLys 745, Thr 790Carbon Hydrogen BondSer 720AlkylLeu 718, Val 726, Ala A: 743, Leu 844Pi- SigmaMet 766Pi-Pi T-shapedPhe 856Halogen(Fluorine)Cys 775, Arg 776DHFRC10−8.6Carbon Hydrogen BondTyr 121AlkylLeu 22, Lys 55C20−9.1Carbon Hydrogen BondAla 9AlkylLeu 22,Phe 34, Lys 55C29−8.4Carbon Hydrogen BondSer 118AlkylIle 16, Leu 22C92−8.4Conventional Hydrogen BondGly 20AlkylLys 55C95−8.7AlkylIle 16, Leu 22C98−9Conventional Hydrogen BondAla 9Carbon Hydrogen BondVal 8AlkylIle 16, Leu 22, Lys 55Ciprofloxacin−8.2Conventional Hydrogen BondAla 9Carbon Hydrogen BondVal 8, Thr 56, Ser 118AlkylIle 16, Leu 22, Lys 55DORC29−9.5AlkylVal 316, Ala 319, Phe 329C46−9.1Unfavorable Donor-DonorArg 76AlkylVal 68, Leu 69Pi- SigmaPhe 72C95−10.1AlkylVal 62, Leu 69, Val 70, Pro 315, Val 316, Ala 319, Phe 329C96−9.8AlkylMet 71, Val 75C99−9.5Pi- SigmaLeu 69Pi- Pi StackedPhe 329AlkylVal 62, Val 70, Pro 315, Val 316,Ala 319, Leu 332Loperamide−10.2Conventional Hydrogen BondLeu 69AlkylVal 70, Ala 319, Phe 325, Cys 328, Leu 332Pi -Pi StackedPhe 72TNF-alphaC7−8.7Pi- SigmaTyr 59AlkylLeu 57, Tyr 59, Tyr 151C10−9.1Conventional Hydrogen BondSer 60Pi- SigmaTyr 59AlkylLeu 57, Tyr 59, Tyr 151C92−9.5Pi- SigmaTyr 59AlkylTyr 59, Tyr 119, Tyr 151C96−9.8Carbon Hydrogen BondGly 121AlkylAla 96C99−8.7Pi- Pi StackedTyr 59, Tyr 119, Tyr 119AlkylLeu 57Diclofenac−7.1Conventional Hydrogen BondLeu 120Pi- Pi StackedTyr 59, Tyr 119COX-2C4−8.6Carbon Hydrogen BondVal 523,Ser 530Pi- Pi StackedPhe 518, Gly 526AlkylVal 349, Leu 352, Tyr 385, Trp 387, Ala 527, Leu 531C11−8.1AlkylHis 90, Val 116, Val 349, Leu 352, Leu 359, Tyr 385, Trp 387,Ala 516, Met 522, Val 523, Ala 527, Leu 531C14−8Conventional Hydrogen BondSer 530AlkylVal 349, Leu 352, Tyr 385, Trp 387, Phe 518, Met 522, Ala 527C59−8.1AlkylTyr 348, Val 349, Leu 352, Leu 384, Tyr 385, Trp 387, Phe 518, Met 522, Val 523, Ala 527C87−8.7Van der WaalsAla 516Pi- SigmaThr 94Amide -Pi StackedAsp 515AlkylVal 116, Val 349, Leu 352, Leu 359, Tyr 385, Trp 387, Pro 514, Phe 518, Val 523, Ala 527, Leu 531,C99−9.2Pi- SigmaVal 349, Val 523, Ala 527Pi- Pi T -shapedTrp 387AlkylTyr 348, Leu 352, Tyr 355Pi- sulfurMet 522Diclofenac−7.9Conventional Hydrogen BondTyr 355Pi- SigmaVal 349, Ala 527Amide -Pi StackedGly 526AlkylLeu 352, Leu 531 Bond and Binding Site of Highly Active Compounds Against Different Targets Including EGFR, DGFR, DOR, TNF-α, and COX-2 Molecular Interactions of Phytochemicals with EGFR enzyme with the most prominent phytocompounds, here (A) interactions of Compound 46 and EGFR enzyme, (B) interactions of Compound 53 and EGFR enzyme, (C) interactions of Compound 92 and EGFR enzyme, (D) interactions of Compound 95 and EGFR enzyme, (E) interactions of standard Lapatinib and EGFR. Bacterial DHFR, crucial for thymidylate biosynthesis in the folic acid pathway, is a promising target for treating infections. Inhibitors targeting DHFR may induce bacterial death, offering a potential avenue for infection treatment.95 Concerning DHFR, C20 demonstrated a robust interaction, forming a carbon-hydrogen bond and three alkyl bonds, resulting in an impressive binding score of −9.1 kcal/mol, surpassing the affinity of Ciprofloxacin, which scored −8.2 kcal/mol (Table 8, Figure 8). Additionally, C10 and C29 established bonds with the receptor through alkyl and carbon-hydrogen interactions, displaying binding scores of −8.6 and −9.1 kcal/mol, respectively. Figure 8Molecular Interactions of Phytochemicals with DHFR enzyme with the most prominent phytocompounds, here (A) interactions of Compound 10 and DHFR enzyme, (B) interactions of Compound 20 and DHFR enzyme, (C) interactions of Compound 95 and DHFR enzyme, (D) interactions of Compound 99 and DHFR enzyme, (E) interactions of standard Ciprofloxacin and DHFR. Molecular Interactions of Phytochemicals with DHFR enzyme with the most prominent phytocompounds, here (A) interactions of Compound 10 and DHFR enzyme, (B) interactions of Compound 20 and DHFR enzyme, (C) interactions of Compound 95 and DHFR enzyme, (D) interactions of Compound 99 and DHFR enzyme, (E) interactions of standard Ciprofloxacin and DHFR. The opioid receptors (µ, ƙ, and δ) in the human gastrointestinal (GI) tract significantly impact GI signaling. They work by inhibiting enteric nerve activity, blocking neurotransmitter release, and disrupting excitatory and inhibitory motor pathways. This causes a slowing down of intestinal transit, decreased excitability of enteric neurons, and changes in fluid transport and secretion mechanisms. These complex alterations ultimately lead to variations in GI motility and stool consistency.96 Numerous compounds identified in the study demonstrated notable activity against DOR, with C95 and C96 standing out with the highest affinities, scoring −10.1 and −9.8 kcal/mol, respectively. They achieved this through the formation of different bonds like alkyl, pi-sigma, and unfavorable donor donors. In contrast, Loperamide established conventional hydrogen, alkyl, and pi-stacked bonds, resulting in a binding score of −10.2 kcal/mol (Table 8, Figure 9). Figure 9Molecular Interactions of Phytochemicals with DOR enzyme with the most prominent phytocompounds, here (A) interactions of Compound 29 and DOR enzyme, (B) interactions of Compound 95 and DOR enzyme, (C) interactions of Compound 96 and DOR enzyme, (D) interactions of Compound 99 and DOR enzyme, (E) interactions of standard Loperamide and DOR. Molecular Interactions of Phytochemicals with DOR enzyme with the most prominent phytocompounds, here (A) interactions of Compound 29 and DOR enzyme, (B) interactions of Compound 95 and DOR enzyme, (C) interactions of Compound 96 and DOR enzyme, (D) interactions of Compound 99 and DOR enzyme, (E) interactions of standard Loperamide and DOR. Inflammation is a physiological response to injury or infection, with acute inflammation involving cytokines and neutrophils. Chronic inflammation, involving additional immune cells, is associated with diseases, including cancer. TNF-α plays a crucial role in inflammation by activating NF-ƙB, leading to the expression of various inflammatory genes. TNF-α produced in the tumor microenvironment can promote tumor cell survival and contribute to multiple steps in tumorigenesis, including cellular transformation, promotion, proliferation, invasion, angiogenesis, and metastasis.97 With a remarkable binding score of −9.8 kcal/mol, C96 displayed the highest affinity towards TNF-α, forming interactions through a single carbon-hydrogen bond and alkyl bonds (Table 8, Figure 10). Notably, numerous identified compounds showed significant suppression of the docking score compared to the standard diclofenac. This suggests the potential for a potent anti-inflammatory effect from the plant crude extract. Figure 10Molecular Interactions of Phytochemicals with TNF-α enzyme with the most prominent phytocompounds, here (A) interactions of Compound 7 and TNF-α enzyme, (B) interactions of Compound 10 and TNF-α enzyme, (C) interactions of Compound 92 and TNF-α enzyme, (D) interactions of Compound 96 and TNF-α enzyme, (E) interactions of Compound 99 and TNF-α enzyme, (F) interactions of standard Diclofenac and TNF-α enzyme. Molecular Interactions of Phytochemicals with TNF-α enzyme with the most prominent phytocompounds, here (A) interactions of Compound 7 and TNF-α enzyme, (B) interactions of Compound 10 and TNF-α enzyme, (C) interactions of Compound 92 and TNF-α enzyme, (D) interactions of Compound 96 and TNF-α enzyme, (E) interactions of Compound 99 and TNF-α enzyme, (F) interactions of standard Diclofenac and TNF-α enzyme. COX-2, or cyclooxygenase-2, is implicated in inflammation as it generates prostaglandins that play a pro-inflammatory role during the initial stages of inflammation. However, recent studies suggest that later-stage COX-2-generated prostaglandins may contribute to the resolution of inflammation, indicating a dual role in the inflammatory process. Inhibition of COX-2 has been shown to reduce inflammation in certain experimental models, highlighting its complex involvement in inflammatory responses.98 Like TNF-α, various identified compounds demonstrated the suppression of the standard diclofenac binding score towards COX-2, indicating the potential for analgesic activities in the plant extract. Notably, C99 exhibited the highest affinity, interacting through four different bond types: pi-sigma, pi-pi, pi-sulfur, and alkyl (Table 8, Figure 11). Conversely, C87, with a score of −8.7 kcal/mol, displayed the second-highest activity toward the receptor, forming bonds such as van der Waals, pi-sigma, amide-pi, and alkyl bonds. Figure 11Molecular Interactions of Phytochemicals with COX-2 enzyme with the most prominent phytocompounds, here (A) interactions of Compound 4 and COX-2 enzyme, (B) interactions of Compound 11 and COX-2 enzyme, (C) interactions of Compound 59 and COX-2 enzyme, (D) interactions of Compound 87 and COX-2 enzyme, (E) interactions of Compound 99 and COX-2 enzyme, (F) interactions of standard Diclofenac and COX-2. Molecular Interactions of Phytochemicals with COX-2 enzyme with the most prominent phytocompounds, here (A) interactions of Compound 4 and COX-2 enzyme, (B) interactions of Compound 11 and COX-2 enzyme, (C) interactions of Compound 59 and COX-2 enzyme, (D) interactions of Compound 87 and COX-2 enzyme, (E) interactions of Compound 99 and COX-2 enzyme, (F) interactions of standard Diclofenac and COX-2. The ADMET study was conducted to determine the drug-likeness profile of the most active compounds, assessing their potential as drug candidates. This analysis included evaluating pharmacokinetic properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET), which are essential for understanding the pharmacological properties of substances and their suitability for drug development.99 Table 9 demonstrate that C4, C14, C29, C89, and C98 exhibit high GI absorption with favorable drug-likeness profiles. These compounds have moderate lipophilicity, as indicated by their log P values (between 2.97 and 5.21), making them potentially suitable for oral administration. Notably, C29 and C98 meet all drug-likeness criteria, signifying their potential as orally bioavailable therapeutic agents. Compounds such as C7, C11, C53, and C96 have lower GI absorption, which may impact their oral bioavailability. In particular, C11, with a high lipophilicity (log P = 6.31) and more than seven rotatable bonds, may have reduced intestinal permeability and an unfavorable pharmacokinetic profile. Similarly, C53 and C96 also have high lipophilicity (log P values >5), which could limit their absorption and distribution. Concerning hepatotoxicity, most compounds were non-hepatotoxic, suggesting a favorable safety profile for potential liver toxicity. However, compounds C10, C20, and C89 exhibit AMES toxicity, indicating possible mutagenic properties that could limit their therapeutic applications without further structural modifications or alternative usage routes. In terms of drug-likeness, violations of the Lipinski Rule of Five were observed in compounds with either high molecular weight (eg, C20, C46, C87, C92, C96) or elevated log P values (eg, C7, C10, C11, C20, C53, C87, C89, C95, C96, C99). These violations suggest potential challenges in achieving optimal bioavailability and metabolic stability, especially for highly lipophilic compounds. Overall, C4, C14, C29, and C98 emerge as favorable candidates, demonstrating high GI absorption, minimal toxicity, and compliance with drug-likeness criteria. Future studies may focus on optimizing these compounds to enhance their bioavailability while mitigating any potential toxic effects indicated by their ADME/T profiles. Table 9ADMET Analysis Result of the Best-Bonded Compounds of Leaves of Canna IndicaCompound NoH-bond DonorH-bond AcceptorsLipophilicity - log P (o/w)GI AbsorptionAMES ToxicityHepatotoxicityDrug likelinessBioavailability scoreC4023.37HighNoNo0.55No; 1 violation: MW<250C7005.45LowNoNo0.55No; 1 violation: XLOGP3>3.5C10133.88HighNoYes0.55No; 1 violation: XLOGP3>3.5C11126.31LowNoNo0.55No; 2 violations: Rotors>7, XLOGP3>3.5C14022.97HighNoNo0.55No; 1 violation: MW<250C20135.33HighNoYes0.55No; 2 violations: MW>350, XLOGP3>3.5C29133.09HighNoNo0.55YesC46464.22HighNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C53015.85LowNoYes0.55No; 1 violation: XLOGP3>3.5C871310.72HighNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C89015.21HighNoYes0.55No; 1 violation: XLOGP3>3.5C92026.57LowNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C95014.96HighNoYes0.55No; 1 violation: XLOGP3>3.5C96016.7LowNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C98123.71HighNoYes0.55YesC99115.83HighYesYes0.55No; 1 violation: XLOGP3>3.5 Table 9ADMET Analysis Result of the Best-Bonded Compounds of Leaves of Canna IndicaCompound NoH-bond DonorH-bond AcceptorsLipophilicity - log P (o/w)GI AbsorptionAMES ToxicityHepatotoxicityDrug likelinessBioavailability scoreC4023.37HighNoNo0.55No; 1 violation: MW<250C7005.45LowNoNo0.55No; 1 violation: XLOGP3>3.5C10133.88HighNoYes0.55No; 1 violation: XLOGP3>3.5C11126.31LowNoNo0.55No; 2 violations: Rotors>7, XLOGP3>3.5C14022.97HighNoNo0.55No; 1 violation: MW<250C20135.33HighNoYes0.55No; 2 violations: MW>350, XLOGP3>3.5C29133.09HighNoNo0.55YesC46464.22HighNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C53015.85LowNoYes0.55No; 1 violation: XLOGP3>3.5C871310.72HighNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C89015.21HighNoYes0.55No; 1 violation: XLOGP3>3.5C92026.57LowNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C95014.96HighNoYes0.55No; 1 violation: XLOGP3>3.5C96016.7LowNoNo0.55No; 2 violations: MW>350, XLOGP3>3.5C98123.71HighNoYes0.55YesC99115.83HighYesYes0.55No; 1 violation: XLOGP3>3.5 ADMET Analysis Result of the Best-Bonded Compounds of Leaves of Canna Indica These interpretations are significant for the discovery of novel medicinal products, clinical trials, and the biological analysis of isolated compounds. The study emphasizes that compounds adhering to pharmacokinetic and toxicological criteria can be potent candidates for drug discovery, particularly for oral use, and safer for therapeutic applications. The findings suggest that the investigated compounds possess attributes rendering them promising contenders for drug development targeting a range of health concerns, including cancer, diarrhea, microbial infections, inflammation, and pain management. While these initial outcomes are positive, further preclinical investigations involving animal experiments and clinical trials with human subjects are essential to thoroughly evaluate the efficacy and safety of these potential treatments. These supplementary studies are crucial to substantiate the potential therapeutic applications of these substances and pave the way for developing potent drugs addressing various illnesses. In summary, this study highlights several promising phytochemicals from C. indica leaf extracts that exhibit significant biological activities, underscoring their potential applications in drug development. Among the compounds analyzed, C99, C96, and C20 demonstrated notable pharmacological properties. Specifically, C99 showed strong affinity for both COX-2 and EGFR, indicating potential roles in anti-inflammatory and anticancer applications. C96 exhibited the highest binding affinity toward TNF-α, which suggests an effective anti-inflammatory action, while C20 showed promising binding interactions with DHFR, which is crucial in targeting bacterial infections. Furthermore, ADMET analysis indicated that C29 and C98 meet Lipinski’s Rule of Five, suggesting high oral bioavailability, although some compounds, such as C99, showed hepatotoxicity, which necessitates further investigation for safety. These findings collectively illustrate the therapeutic potential of C. indica extracts, with key compounds emerging as candidates for anti-inflammatory, antimicrobial, and anticancer drug development. However, additional studies, including clinical trials and in-depth toxicological assessments, are essential to validate these effects and ensure safety in human applications. By expanding research on these bioactive compounds, this study lays a foundation for the future exploration of C. indica as a valuable source for natural drug development. Limitations While this research demonstrates promising findings for C. indica leaf extracts, several limitations warrant careful consideration. Although animal models, particularly mice, were used to investigate the antidiarrheal and analgesic effects, translating these results to human applications requires caution. Further examination of potential synergistic effects within the extract could deepen our understanding of its pharmacological profile. Conducting human clinical trials will be essential to accurately assess the extract’s efficacy, safety, and optimal dosing in humans. Additionally, the complex processes involved in drug discovery and development underscore the importance of understanding the ADME properties, as these are fundamental to predicting drug behavior in the body. Drug metabolism studies, in particular, are vital to identifying active metabolites, addressing safety concerns, and refining dosage guidelines. Incorporating in silico data may also provide valuable leads for further research, supporting these efforts. In summary, while this study offers significant insights, future research, including human clinical trials, will be crucial for substantiating and expanding upon these findings, advancing the potential of C. indica in natural medicine. Conclusion This comprehensive exploration highlights the impressive pharmacological versatility of Canna indica L. leaves, emphasizing their substantial therapeutic potential through significant bioactivities, including antidiarrheal, antimicrobial, analgesic, and cytotoxic properties. In our study, EASF and DCMSF fractions of C. indica demonstrated strong cytotoxic effects against brine shrimp, with LC50 values suggesting anti-cancer potential. Additionally, the AQSF fraction showed antimicrobial efficacy, albeit lower than standard antibiotics, supporting the need for bioassay-guided isolation of potent antimicrobial agents. Antidiarrheal activity was observed in DCMSF and AQSF, likely through inhibition of intestinal inflammation. On the other hand, Compounds C99, C96, and C20 exhibited notable pharmacological properties, with C99 showing strong affinity for COX-2 and EGFR, suggesting anti-inflammatory and anticancer potential. C96 demonstrated the highest binding affinity for TNF-α, indicating effective anti-inflammatory action, while C20 showed promising interactions with DHFR, a critical target in combating bacterial infections. ADMET analysis further revealed that compounds C29 and C98 meet Lipinski’s Rule of Five, suggesting good oral bioavailability, though C99 requires additional safety evaluation due to indications of hepatotoxicity. The multi-target activities of these compounds not only enhance the overall pharmacological effects of the leaf extract but also pave the way for exciting future research and pharmaceutical applications. To build on these findings, future studies should focus on in vivo efficacy, mechanisms of action, and formulation development to further elucidate the therapeutic potential of C. indica extracts. These efforts could ultimately yield promising leads for clinical trials. Given the compelling evidence, C. indica leaves present a significant opportunity for the development of new medicinal products, advancing the pursuit of innovative and effective treatments.